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Sporadic Parkinson’s disease (PD) is the most widely recognized and second 
most common movement disorder (Fahn, 2010). It is known as an older 
person’s disease, affecting 2–3% of the population 65 years of age or older 
(Poewe et al., 2017). PD is characterized by a selective, dynamic, progressive 
loss of dopaminergic neurons in the substantia nigra (SN).  
PD clinical features are defined by both motor (bradykinesia, along with 
resting tremor and/or rigidity) and non-motor symptoms (e.g. constipation, 
apathy, fatigue, olfactory dysfunction, REM sleep behavior disorders (RBD), 
depression and cognitive decline) which become more severe as the disease 
advances. Treatment of PD is based on pharmacological substitution of striatal 
dopamine, in addition to non-dopaminergic approaches to address both motor 
and non-motor symptoms and deep brain stimulation for those developing 
medically untreatable L-DOPA-related motor complications.  
The majority of PD cases are idiopathic, which means that there is not one 
specific cause but most probably several mechanisms have contributed to the 
pathogenesis including a genetic vulnerability, metabolic abnormalities, 
environmental factors and possibly infections (Hernandez et al., 2016). The 
effectiveness of establishing a clinical diagnosis of PD by a PD specialist has 
been reported to be over 90% in clinicopathological studies (Hughes et al., 
2002). The new Movement Disorders Society (MDS) criteria for the diagnosis 
of PD (Postuma et al., 2015a) have been shown to lead to even better diagnostic 
accuracy (Postuma et al., 2018). Since Becker’s 1995 study, much research has 
focused on the substantia nigra hyperechogenicity (SN+) and the diagnostic 
accuracy of transcranial sonography (TCS) in distinguishing PD patients from 
healthy controls. In more than 90% of PD patients, TCS reveals a characteristic 
SN+, which has been reported to be stable during the course of the disease. SN+ 
has been proposed to be a risk factor for developing PD (Berg et al., 2005; Berg 
et al., 2012; Walter et al., 2007) or a subclinical stage of the disease (Walter, 
2004). Reported cut-off values for the discrimination between normal echo-
genicity and SN+ with different contemporary ultrasound systems are known in 
the literature (Walter et al., 2014b). Even so, the sensitivity and specificity of 
TCS in PD diverge widely due to ethnicity, representative size and diverse 
ultrasound devices. The normal ranges of SN+ need to be established for each 
lab because of some potential investigator dependency.  
The first aim of this study was to validate SN+ in a large Estonian cohort. 
About 10% of the total number of Estonian PD patients were enrolled in the 
study. The importance of the study lies in the fact that validated SN+ data 
creates a valuable basis for future scientific research in the Estonian cohort.  
The severity of depressive symptoms is an important factor in modulating 
the clinical aspects of PD. With an average prevalence of about 40%, ranging 
from 27% to 76%, depression is one of the most common non-motor mani-
festations of PD (Ji Won Han et al., 2018; Kadastik-Eerme et al., 2016; 
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Slaughter et al., 2001; Reijnders et al., 2008). The onset of depression during 
the late stages of PD has been argued to be mainly related to a broader 
monoaminergic deficit in combination with a higher occurrence of cognitive 
impairment (Braak et al., 2004). Depressive symptoms often remain untreated 
in PD patients (van der Hoek et al., 2011), underlining the need to recognize 
early biomarkers associated with depression in PD. The level of affective 
disorders was directly related to the anatomical changes in the brainstem raphe 
(Walter, 2007b). In healthy individuals, the mesencephalic part of the midline 
raphe is visualized as a continuous hyperechogenic line which is located in the 
middle of the mesencephalon. Raphe echogenicity should only be classified as 
reduced if TCS from both sides shows reduced echogenicity under adequate 
imaging conditions. Decreased echogenicity of the mesencephalic raphe has 
been found in 40%–60% of patients with PD having depression (Becker et al., 
1997; Berg et al., 1999; Walter et al., 2007b). Therefore, the second aim of this 
study was to describe the prevalence and severity of depressive symptoms in 
Estonian PD patients and their possible associations with brainstem raphe 
echogenicity.  
A negative correlation between age of disease onset and SN+ was previously 
reported (Walter et al., 2007a). An association between age of disease onset and 
SN+ area has not yet been convincingly demonstrated. On the other hand, the 
first two studies on TCS in PD showed no correlation between the size of the 
SN+ and age (Berg et al., 2001), but in patients with RBD (Iranzo et al., 2007) 
were demonstrated an increasing prevalence of SN+ with age in elderly 
individuals. Ageing may represent various stressors within SN+, weakening 
and/or causing loss of neuron function and their ability to react to further 
damages associated with the disease progression. Moreover, it can be 
speculated that an enlarged SN+ at the onset stage of PD results from active 
neuroinflammatory processes, which gradually diminish with the progression of 
PD and the decrease in the number of dopaminergic cells. Therefore, the study’s 
third aim was to evaluate whether SN+ values are different on the respective 
sides mirroring the asymmetric character of the disease and to evaluate SN+ in 






2. LITERATURE REVIEW 
2.1. PD epidemiology in Estonia 
The age-adjusted prevalence of PD in Estonia was 152 per 100,000 population, 
159 for urban and 139 for the rural group, 154 for men and 153 for women in 
1996 (Taba et al., 2002). The age-specific prevalence increased from 22 per 
100,000 individuals in the age group 40–49 years up to 1,232 per 100,000 
individuals in the age group 70–79 years. The mean age of PD patients was 
71.4 years, the mean age at onset of the symptoms was 66.9 years (Taba et al., 
2002) and the most recent data shows the same age specific prevalence (Taba et 
al., 2002; Kadastik-Eerme et al., 2018). But the overall disease prevalence in 
Estonia has increased from 152 per 100,000 individuals in 1996 to 197 per 
100,000 individuals in 2013 (Kadastik-Eerme et al., 2018). When comparing 
the prevalence rates with other studies of Caucasian populations in Europe, the 
results are except for slightly similar (Kadastik-Eerme et al., 2018) but not 
significantly higher prevalence rates in the urban population in Estonia 
(Kadastik-Eerme et al., 2018). 
 
 
2.2. Natural history of PD 
The process of neurodegeneration in PD begins long before the onset of clinical 
motor symptoms, resulting in substantial cell loss by the time a diagnosis can be 
made. The period between the onset of neurodegeneration and the development 
of motoric disease would be the ideal time to intervene with disease modifying 
therapies.  
The pathological hallmark of the disease is the presence of Lewy bodies 
(LB) within the SN and other parts of the brain, containing intracellular 
aggregations of misfolded αsyn. The anatomical origin of the disease process, 
however, is likely to be further afield, perhaps even outside of the brain (Braak 
et al., 2003; Braak et al., 2008). Braak’s hypothesis suggests that neuro-
degeneration is initiated in the lower brainstem and anterior olfactory structures 
before ascending to the basal ganglia and cortical areas in a characteristic 
sequence. In keeping with this, non-motor symptoms such as hyposmia, 
autonomic failure and sleep disturbances commonly emerge many years before 
motor parkinsonism (Postuma et al., 2016b). The importance of developing 
reliable methods for diagnosis during this pre-motor phase is underlined by the 
observation that >50% of nigral dopaminergic neurons and up to 80% of 
nigrostriatal synaptic activity have been lost by the time the motor phenotype 
emerges (Fearnley et al., 1991; Fernandez et al., 2011). Postmortem and 
neuroimaging studies suggest that degeneration within the basal ganglia may 
commence up to 7 years prior to diagnosis (Hawkes, 2008; Morrish et al., 
1998), but prodromal symptoms such as hyposmia and REM sleep behaviour 
 
13 
disorder can emerge decades earlier in some cases (Iranzo et al., 2013; Schenck 
et al., 2013a,b). Techniques such as TCS of the SN have great potential to 
facilitate early diagnosis. 
 
 
2.3. TCS as preclinical marker and  
an approach to early diagnosis 
A few years ago, a task force of the Movement Disorders Society, building on 
previous systems (Berg et al., 2013; Obeso et al., 2017; Postuma et al., 2018) 
divided early PD into the following 3 stages: 
(1) Preclinical: neurodegeneration is present but without measurable symp-
toms or signs – biomarker diagnosis required (Postuma, 2015b). By defi-
nition, patients are not just in an at-risk state (e.g., young persons with 
highly penetrant gene mutations). 
(2) Prodromal: symptoms/signs are present, but they are insufficient to 
diagnose clinical PD. 
(3) Clinical: this implies the presence of parkinsonism. Most markers of 
prodromal PD directly reflect symptoms and signs; some can be detected 
clinically, whereas others need biomarker confirmation (e.g., polysomno-
graphy). In PD, the SN has abnormally high SN+ on ultrasound imaging 
(Gaenslen, 2008). Whether this hyperechogenicity is a risk marker or a 
prodromal marker is unclear. Hyperechogenicity can be detected at an 
early age and does not progress with disease duration, suggesting that it is a 
risk marker (Iova et al., 2004).  
 
In any case, it seems that SN+ may be a valuable tool to detect an increased 
vulnerability for PD. In one population-based study, SN+ was associated with a 
20-fold increase in the risk of PD (Berg et al., 2012). In comparison with other 
neuroimaging procedures, ultrasound is inexpensive, but requires specialist 




2.4. Pathology and pathogenesis 
2.4.1. Pathophysiology of PD 
Historically, PD has been considered a ‘motor’ disease linked to degeneration 
of midbrain dopaminergic neurons. Characteristic features of PD include 
neuronal loss in specific areas of the SN and widespread intracellular protein 
αsyn accumulation. Although neither the loss of pigmented dopaminergic 
neurons in SN (Titova et al., 2017) nor the deposition of αsyn in neurons is 
specific for PD, these two major neuropathologies are specific for a definitive 
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diagnosis of PD when applied together (Poewe et al., 2017). The multi-focal 
and multi-neurotransmitter driven pathology of PD has been emphasized by the 
landmark work of Braak and colleagues (Braak et al., 2003) who suggested that 
a ‘bottom-up’ six-stage pathological process could account for most cases 
studied neuropathologically (Titova et al., 2017; Braak et al., 2003). This work 
has proposed that αsyn pathology critically resulting in neuronal LB deposition 
and cell death spreads from regions interfacing with the ‘environment’. In this 
model, regions including the olfactory bulb and the enteric nervous system with 
its connections to the medulla through the dorsal motor nucleus of the vagus 
nerve act as a ‘conduit’ for a spreading pathology perhaps mediated by a prion-
like process (Titova et al., 2017). Such a model allows both dopaminergic and 
non-dopaminergic populations to be differentially affected and in so doing may 
permit insights into the motor and non-motor symptoms. Whilst by no means 
perfect, this concept of a multi-neurotransmitter, multi-organ (brain and peri-
pheral nervous system) disorder is now well established in the literature with 
supportive pathological and biomarker driven projects (Titova et al., 2017). 
Inflammation and neuronal death in PD are clear evidence for activation of both 
the innate and adaptive arms of the immune system. In the brain, the cells 
primarily responsible for innate immunity are the resident microglia, involved 
in constant surveillance of the brain microenvironment. Postmortem studies of 
PD-affected brains and PD model systems consistently demonstrate striking 
microglial activation (Obeso et al., 2017; McGeer et al., 2008).  
 
 
2.5. PD symptoms 
2.5.1. PD motor symptoms 
PD is an extremely heterogeneous disorder which is defined by the presence of 
classical motor features, including the hallmark presence of bradykinesia in all 
patients, rigidity and rest tremor in the majority. The unilateral onset of rest 
tremor is a phenomenon we still use today as an essential element of clinical 
diagnostic criteria for PD (Gibb et al., 1988; Obeso et al., 2017; Postuma et al., 
2015b). The other types are clinically characterized by a postural and action 
tremor, which is mainly associated with tremor at rest, but the action tremor 
often has a higher frequency and may be disabling in daily activities. A further 
high-frequency action tremor is clinically associated with rigidity (Deuschl et 
al., 2008; Obeso et al., 2017). Parkinsonian tremor is the most specific sign of 
PD and likely occurs in more than 90% of PD patients at some time during the 
course of the disease (Obeso et al., 2017). However, it shows no correlation 
with the progression of rigidity and akinesia scores(Obeso, 2017). PD tremor 
may not be as reliably responsive to dopamine replacement therapy as other 
typical motor signs. Although in many cases there is a good and reproducible 
response to Levodopa, there is also a significant percentage of patients who do 
not respond significantly enough to make treatment worthwhile. 
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Postural reflex disturbances include flexed postures of the trunk and limbs as 
well as postural instability, which generally occur later in the disease 
progression and are no longer considered essential diagnostic features.  
Bradykinesia, impaired posture and balance, and rigidity are the criteria on 
which we rest a clinical diagnosis of PD today. Sometimes a patient may speak 
softly, quickly, slur or hesitate before talking. Patient speech may be more 
monotonous, lacking the usual inflections. There may be changes in writing, such 
as increased difficulty and writing appearing small.  
As the disease progresses, the clinical picture becomes a complex of 
levodopa-related motor complications, non-dopaminergic motor features such 
as speech and swallowing problems, freezing of gait and falls, and increasingly 
disabling non-motor symptoms including autonomic failure, psychiatric 
disturbances, and dementia. 
 
 
2.5.2. Non-motor symptoms in PD 
Today a large variety of nonmotor symptoms are considered an integral part of 
the disease, and there is strong evidence that some of these, such as hyposmia, 
constipation, or rapid eye movement (REM) sleep behavioral disorder and 
depression may even be the earliest manifestations of the disease, occurring 
years before any of the defining motor features are present (Obeso et al., 2017; 
Pont-Sunyer et al., 2015).  
The initial studies (Szeto et al., 2015) highlighted that whilst tremor domi-
nant patients are relatively spared from non-motor symptoms, the non-tremor 
dominant subgroup is more associated with cognitive impairment and mood 
disturbance. Indeed, a more recent study has identified a differential expression 
of mild cognitive impairment across these subgroups, with the highest fre-
quency observed in the non-tremor dominant cluster, which was also associated 
with a higher prevalence of freezing of gait, hallucinations, daytime somno-
lence, and rapid behaviour disorder (RBD) compared with other subgroups 
(Szeto et al., 2015).  
Several medical records have demonstrated diagnosis of depression often 
preceding the diagnosis of PD; estimates of the predictive value are similar, 
with an relative risk (RR) of 1.5–2.5 (Postuma et al., 2016b). Depression and 
anxiety are commonly comorbid in PD, so they will be considered together. 
Phobic anxiety and anxious personality traits have been associated with a  
1.5-fold increase in the risk of PD (Postuma et al., 2016b). These low relative 
risks imply that predictive value is low. Many studies document that both mood 
disorders are associated with higher PD risk, but the RR is low, ranging from 
1.5 to 2.5, with resulting low specificity (Berg et al., 2015). The lead time is 
unclear; it may be biphasic with an early tendency toward anxiety (e.g., the 
putative Parkinson personality) combined with a second episode of depression 
emerging soon before PD onset (Gustafsson et al., 2015; Emre et al., 2004). In 
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striking contrast to clinical markers, evidence for blood or cerebrospinal fluid 
variables as prodromal markers is extremely limited, although this may change 
in the near future for specific types of PD (Vilas et al., 2016). 
 
 
2.6. Neuroimaging in PD  
Neuroimaging in PD includes morphological imaging using magnetic resonance 
imaging (MRI) and TCS and functional techniques like positron emission 
tomography (PET) and single photon emission computed tomography (SPECT) 
to probe different aspects of the neurobiology of PD. Brain imaging is 
not routinely recommended in all patients with PD (Ransohoff et al., 2016).  
 
 
2.6.1. MRI as the structural imaging 
MRI has been extensively used in the imaging of parkinsonian syndromes. 
Besides the conventional MRI sequences, recent advanced techniques including 
diffusion weighted imaging with tensor imaging, magnet resonance morpho-
metry, magnetisation transfer imaging and magnet resonance spectroscopy have 
also been used in the diagnosis of these group of disorders. Imaging is helpful to 
confirm the diagnosis of parkinsonian syndromes, classify them into various 
subtypes, rule out the alternative differential diagnosis and determine the 
severity of brain changes (Savoirado, 2003). 
The conventional T1 and T2 weighted MRI, especially at 1.5 Tesla strength, 
are often normal in PD. The MRI is more often used to rule out other conditions 
like demyelination, vascular insults and normal pressure hydrocephalus. The 
advanced cases may show hyperintense signal changes on T2 weighted images 
in bilateral substantia nigra as the only finding (Savoirado, 2003). Some 
advanced MRI imaging may be helpful methods to differentiate parkinsonian 
syndromes from PD.  
Traditional structural imaging does not generally reveal significant repro-
ducible changes in PD. Reduced size and signal intensity of the SN were 
reported in PD patients using neuromelanin-sensitive imaging with a high 
diagnostic accuracy. Both techniques may be used in clinical practice as these 
changes can be detected by simple radiological reading. A combination of 
measures, for example, increased iron content and reduced fractional anisotropy, 
changes in nigrosome-1 containing area or neuromelanin imaging, may result in 
better separation of PD patients from control subjects as compared with each 
technique separately (Peran et al., 2010). High-resolution spin echo T1-
weighted images are sensitive to neuromelanin and show the SN as an area of 
high signal intensity (Castellanos et al., 2015). Recent results using functional 
MRI at rest have also shown that the average connectivity in the basal ganglia 
may distinguish patients with PD from healthy controls (Obeso et al., 2017; 
Szewczyk et al., 2014). 
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2.6.2. MRI for differentiating between PD and atypical parkinsonism 
In neurological practice sometimes an MRI brain scan might be valuable for 
patients with atypical features for PD. An MRI some of the time helps in 
patients with parkinsonian disorders – more established patients may have 
markers of progressive supranuclear palsy (PSP), multisystem atrophy (MSA), 
corticobasal degeneration (CBD) and vascular disease (Ramirez et al., 2006). 
Changes in PSP prevalent superior cerebellar peduncle and midbrain atrophy 
(Cebrian et al., 2014; Schapansky et al., 2014). Parkinsonian-type MSA is 
generally more prominent including atrophy, increased iron load, increased 
diffusivity and signal changes in specific brain regions (Obeso et al., 2017 ). In 
parkinsonian-type disorders, MSA can recognize specific abnormalities, for 
example the ‘hot-cross bun’ sign and decreased T2 signal of the putamen in 
MSA. However, their use in clinical practice remains limited because of the 
lack of normative databases and availability of these techniques in clinical 
centers (Obeso, et al. 2017). 
 
 
2.6.3. Radiotracer imaging 
The use of radiotracer imaging may play a relatively limited role in routine 
clinical diagnostics as it is sometimes difficult to be certain of a diagnosis, 
particularly in the early stages of a disease and may therefore be extremely 
useful for selecting patients to participate in trials of disease-modifying 
therapies, where a reliance on clinical assessment may result in the inclusion of 
approximately 15% of patients who do not have dopamine deficiency (Obeso et 
al., 2017). Radiotracer imaging as functional imaging in PD using a 123 I 
Ioflpane (DaTscan) tracer is outstanding in clinical practice, which leads to 
nigrostriatal dopaminergic denervation and loss of the typical pattern on a 
DaTscan (Gao et al., 2008; Ma et al., 2016). Dopaminergic PET/SPECT shows 
a 35% to 65% loss of innervation at diagnosis, implying that milder loss should 
be evident earlier (Obeso et al., 2017). Several studies document abnormalities 
in about 40% of patients with idiopathic RBD, which appear to progress over 
time (Bradley et al., 2010). Moreover, in the Parkinson At-Risk Study, patients 
with dopaminergic denervation had more hyposmia and constipation (Jennings 
et al., 2014). A follow-up, published in abstract form only, found that those who 
had innervation below 65% of expected values had a 20-fold increased risk of 
developing PD (Jennings, 2015). If confirmed, this would imply that dopamine 
transporter scanning is second only to idiopathic RBD in positive predictive 
value for PD (Jennings, 2015). 
DaTscan imaging of presynaptic dopaminergic function shows a charac-
teristic pattern of asymmetric involvement, with a rostral-caudal gradient in 
which the posterior putamen is maximally affected. However, although the 
preferential involvement of putamen over caudate is typical of PD, presynaptic 
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dopaminergic imaging will not reliably differentiate between PD and atypical 
forms of parkinsonism such as MSA and PSP.  
DaTscan imaging utilizing 123 I-ioflupane has been affirmed by the U.S. 
Food and Drug Administration, the National Institute of Health and Care 
Excellence (NICE) and the American Academy of Neurology (AAN) for the 
DaTscan to differentiate essential tremor from parkinsonian disorders (Hirsch et 
al., 2009; Ransohoff et al., 2016).  
123 Meta-iodobenzylguanidine (123 I-MIBG) cardiac scintigraphy is a 
technique used to evaluate post-ganglionic presynaptic cardiac sympathetic 
nerves in heart diseases through a false neurotransmitter analogous to 
norepinephrine. There is a significantly lower heart-to-mediastinum average 
count ratio in patients with PD than atypical parkinsonian disorders, as the 
degree of MIBG uptake reflects postganglionic sympathetic cardiac nerve 
damage in PD (Sampson et al., 2016). Patients diagnosed as having PD but who 
have a normal DaTscan are often referred to as having scans without evidence 
of dopaminergic deficit (SWEDDs). Patients with asymmetric rest tremor and a 
normal DaTSCAN represent a relatively common situation which can be 
misdiagnosed as PD. It has been shown that SWEDDs represent a very 
heterogeneous group of disorders: some of these patients have dystonic tremor 
(Batla et al., 2014; Obeso et al., 2017), whereas others develop an abnormal 
DaTscan at a later follow-up, raising the possibility of either benign tremulous 
PD or false-negative initial DaTscans (Batla et al., 2014; Obeso et al., 2017; 
Wile et al., 2016). 
 
 
2.7. TCS as a diagnostic tool for PD 
2.7.1. History of TCS in PD 
TCS is a widely used method for the visualization of the brain parenchyma 
through the intact scull. The findings of early studies, implicating a prevalence 
of SN+ in more than 90% of PD patients (Becker et al., 1995; Berg et al., 2001), 
have been repeated by many others (Behnke et al., 2001; Walter et al., 2002; 
Okawa et al., 2007; Doepp et al. 2008; Fernandes et al. 2011; Bouwmans et al., 
2013). Moreover, investigations of patients at different disease stages imply that 
there is no association between area of SN+ and disease severity. Therefore 
SN+ may rather be a vulnerability marker rather than a marker for disease 
progression in PD (Berg et al., 2005). 
 
 
2.7.2. TCS in the clinical practice 
TCS contrasted with other neuroimaging modalities can be performed without 
ionizing radiation with portable machines is noninvasive and is protected to 
movement artifacts. In the field of movement disorders, TCS has been built up 
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principally as a tool for the early diagnosis of PD (Berg et al., 2006; Walter et 
al., 2014b), moreover, the TCS may even be helpful for the preclinical 
identification of people at risk for PD (Berg et al., 2006). In the differential 
diagnosis of PD, the TCS has proven to be reliable and sensitive in detecting 
basal ganglia abnormalities, e.g. of the SN in PD and of lenticular nucleus (LN) 
in atypical parkinsonian syndromes (Walter et al., 2007a; Walter et al., 2014b). 
According to a meta-analysis of five independent TCS studies (Walter, 
2009), the finding of SN+ discriminates PD from atypical parkinsonian 
syndromes with a sensitivity of 92% and a specificity of 80% (Walter, 2009). 
Interestingly, SN+ was observed in about 9% of controls, 16% of essential 
tremor patients and in MSA and PSP as well as in DLB, PDD, and CBD cohorts 
to varying degrees (Fernandes et al., 2015). By combining age at disease 
beginning, asymmetry indices and SN+ , Walter and colleagues (Walter et al. 
2007a; Walter et al. 2009) managed to differentiate PDD from DLB with a 
sensitivity of 96%, a specificity of 80%, and a positive predictive value (PPV) 
of 93% (Walter, 2014). Other findings detected between 66 and 88 percent of 
CBD patients have distinctly SN+, while only between 0–20% of the PSP 
patients presented with this characteristic (Chadery et al., 2018). 78% of 
atypical parkinsonism as well as 23% of PD patients demonstrated hyper-
echogenicity of the lentiforme nucleus (LN+). A combination of LN+ with a 




2.7.3. Causes of SN+ and predisposition 
Postmortem ultrasound examinations compared with biochemical and histo-
logical investigations of the SN disclosed that SN+ area correspond to an 
increasing amount of iron measured by spectroscopy and verified histologically 
(Berg et al., 2002). This association could also be confirmed in vivo by MRI 
investigations determining T2-relaxation times, which are used for the detection 
of elevated iron content in tissue (Berg et al., 2002). Here, patients with PD and 
increased area of SN+ showed decreased T2-relaxation time, corresponding to 
increased iron levels. Also, healthy subjects with SN+ had a significant decrease 
in T2-relaxation times when compared to subjects without this echofeature, 
although values were less reduced compared to PD patients. In normal conditions, 
iron is necessary for the maintenance of physiological function of neurons. 
However, excessive iron deposits in the brain may cause a cascade of events of 
oxidative stress and neuroinflammation that destroy neuronal phospholipid 
membranes, proteins and nucleic acids, leading to the degeneration and death of 
neurons (Shu yang et al., 2018). Thus, a healthy iron level in the brain is vital 
for maintaining a stable internal environment through a rigorous regulatory 
mechanism. Taken together, a good correlation for TCS, MRI and PET data 
could be shown, as healthy subjects with SN+ had a reduced T2-relaxation time 
as well as a reduced 18F-Dopa uptake compared to healthy controls without this 
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echofeature. These changes were less obvious than in patients with idiopathic 
PD and SN+ (Behnke et al., 2005). 
If TCS is suitable to detect preclinical changes of the SN, the question of 
whether there are any preclinical alterations in mutation carriers for mono-
genetic PD is at hand. The first study by Walter showed that all symptomatic 
PD mutations carriers had either moderate or marked SN+. This was also true 
for asymptomatic carriers with abnormal PET findings and half of the 
aymptomatic carriers with normal PET findings displayed SN+, indicating, that 
TCS might be even more sensitive to identifying presymptomatic mutation 
carriers than PET (Walter, 2004). A predisposition for SN+ could also be shown 
for family members of patients with PD in a study comprising 58 first degree 
relatives of PD patients with almost half of them showing the same echofeature 
as their affected relatives. Several of these SN+ subjects showed signs of motor 
retardation, however, without a clinical picture of full-blown PD (Ruprecht-
Dörfler et al., 2003). 
 
 
2.7.4. SN+ pathogenesis in course of PD 
The SN+ is typical in PD patients. However, the SN+ is not the same among all 
affected patients. A predisposition for this ultrasound characteristic, its 
association with a subclinical impairment of the nigrostriatal system and the fact 
that the signal alteration does not change with progression of the disease prove 
the need to establish the relationship between SN+ and the course of PD. The 
following subgroups of PD patients may be proposed: (1) those having a 
stronger predisposition documented by marked SN+ who might represent the 
more genetically determined PD-courses with earlier onset and slower 
progression and (2) those with smaller SN+ showing later disease onset and 
faster disease progression that might be mainly caused by other factors like exo- 
and endotoxins (Schweitzer et al., 2006). The relationship between SN+ and 
demographic information in PD patients is not clear yet. 
Currently TCS is used for detecting subjects at risk for PD. Thus far, there is 
uncertainty regarding the exact moment at which the degenerative process 
starts, and how individuals at risk of reaching the symptomatic PD stages can be 
reliably identified in the earliest stages of the disease. In one recent study, 
comparisons of the demographic variables between the PD SN+ group and the 
PD non-SN+ group suggested that male sex, old age and late disease onsets 
were relevant to SN+ of PD patients. Although the reason for the gender 
difference was hardly explored, estrogen was thought to be involved (Shu yang, 
2018). Estrogen was found to make female individuals less prone to iron 
accumulation by reducing iron levels (Shu yang et al., 2018). SN+ was 
associated with elevated unbound iron (Shu yang et al., 2018), thus female 
individuals more likely have lower SN+. Here, it was also found that older PD 
patients with late disease onset have larger SN+, which might be due to the 
increasingly accumulation of brain iron during the aging process. The 
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hyperechogenicity in SN was not related to disease duration, which was 
supported by another study observing no significant change in hyperechoic area 
even with an interval of 8 years between examinations (Shu yang et al., 2018). 
These results show that disease duration is not a definitive factor in iron 
accumulation and related SN+ in PD patients. In this investigation, echogenicity 
in SN was associated with disease severity, as indicated by the advanced 
Hoehn-Yahr Stage (HYS), and in their previous study, it was found that iron 
induced dopaminergic neurodegeneration through neuroinflammatoty mechanism 
indicated by the over activation of microglia and robust production of neuro-
toxic factors (Shu yang et al., 2018), which might explain why the hyper-
echogenicity revealed by the elevated iron level in SN was correlated with the 
rapid progression of PD reflected by advanced HYS. 
The inter-individual variation of SN echogenicity has been suggested to be 
caused by a variable degree of local iron accumulation and abnormal iron-
protein compounds but also by gliotic changes (Berg et al., 2008; Walter U. et 
al., 2014). Between the ages of 18 and 75, the distribution of SN echogenicity 
can be regarded as nearly constant (Mehnert et al., 2010), even though there are 
reports of a moderate increase during adult life, especially after the age of 80 
(Walter et al., 2014). To rate SN echogenicity in an individual as normal or 
hyperechogenic, the 75th and 90th percentile of measures in the normal 
population are used as a reference (Berg., et al., 2008), and the larger bilaterally 
measured SN+ are used for classification as follows: the normal echogenic 
measured area is below the 75th percentile; the moderately SN+ measured area 
is between the 75th and the 90th percentile; and the markedly SN+ measured 
area is above the 90th percentile. 
 
 
2.8. TCS in movement disorders: quality standards 
2.8.1. Equipment 
For TCS an optimized ultrasound system equipped with a 2.0 to 3.5 MHz 
phased-array transducer is used (Table 1). 
 
Table 1. Recommended ultrasound system settings for TCS, is adapted from ref. Walter 
et al., 2014b, by thesis author Toomsoo, T. 
Parameter Settings 
Image depth 14–16 cm, adapted as needed 
Dynamic range 45–55 dB 
Contour amplification Medium to high 
Time gain compensation Adapted manually as needed  
Image brightness Adapted manually as needed  
Post-processing parameters  Moderate suppression of low echogenic signals 
Frequency 2.0–3.5 MHz, usually 2.5 MHz 
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Applying these parameters the highest image resolution was achieved at a depth 
of 5–9 cm which is the so-called focal zone of the transducer (Walter et al., 
2014b). New contemporary systems achieve a higher image resolution in the 
focal zone of up to 0.7 to ~1.1mm thanks to tissue harmonic imaging (THI). 
(Walter et al., 2014b). The system-specific image processing technologies 
influence distinct measurements such as the assessment of echogenic areas of 
small brain structures. That is why normal ranges especially for SN echogenic 
areas need to be obtained separately for each ultrasound system. The application 
of THI rather than the conventional imaging mode increases the tissue contrast 




2.8.2. Investigation procedures 
The patient is placed in a supine position on an examination chair with a variably 
adjustable lean part. The investigation room should be darkened. The investi-
gator sits behind the patient’s head. For the usually performed transtemporal 
investigation, the TCS transducer is placed on the right temporal bone in front 
of the ear and parallel to the orbitomeatal line in order to obtain a standardized 
axial view of intracranial structures (Fig. 1A, B). 
 
 
A                                                 B
Figure 1A. TCS transducer is placed on the temporal bone in front of the ear and 
parallel to the orbitomeatal line. To scan the SN should be rather parallel to the orbito-
meatal line. Figure 1B. The angle of the probe is too oblique, adapted from ref. Becker 





An important precondition for obtaining valid TCS findings is the identification 
and keeping of the optimum bone window for insonation. For this, the 
transducer is moved near the anterior helix of the ear conch to find the position 
with the best available visualization of brain structures and the contralateral 
skull bone. Once the optimum position has been found, it is kept by pressing the 
transducer as well as the small finger/ulnar edge of the hand firmly against the 
patient’s head throughout the whole examination. Even when applying optimum 
ultrasound systems settings, assessment of intracranial structures may not be or 
only partially be possible due to an insufficient transtemporal bone window 
which is found in 5 to 40 percent of patients depending on age, sex and geo-
graphic origin (Skoloudík et al., 2010). In neurodegenerative diseases trans-




Figure 2. Sketched anatomy of visible brainstem structures on TCS is adapted from ref. 
Becker et al., 1997 by thesis author Toomsoo, T. Transtemporal TCS is usually carried 
out on standardized axial imaging planes. Abbrevations: SN dex, substantia nigra (right 
side), SN sin, substantia nigra (left side), NR, nucleus ruber, BR, brainstem raphe, A, 
aquaductus. 
 
The best-validated method to grade SN echogenicity is the planimetric mea-
surement of the SN echogenic signals on an axial plane (Berg et a., 2008, 
Skoludik et al., 2010, Walter et al., 2013, Walter et al., 2014).  
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2.8.3. Visualization and assessment of SN+ 
The visualization of midbrain structures (SN, raphe) on an axial imaging plane 
is essential for diagnosing movement disorders. Quality criterion of sufficient 
midbrain visualization: The butterfly-shaped midbrain transection surrounded 
by the highly hypoechogenic basal cisterns (cisterna ambiens, cisterna 
quadrigemina, cisterna suprasellaris) is completely displayed. 
The SN echosignals may have a patchy, band-like or sometimes wide oval 
appearance (Figure. 3). Its appearance may slightly vary even in the same 
individual if using different transducer angulations or various ultrasound 
systems (Walter et al., 2013). The best validated method to grade SN echo-
genicity is the planimetric measurement of the SN echogenic signals on an axial 
plane (Walter et al., 2014). The reliability of TCS assessment of the SN mainly 
depends on two factors: (1) the investigator’s experience and skill, which is 
associated with a potential subjective bias, and (2) the quality of the bone 
window (Berg et al., 2008; Školoudík et al., 2007). The influence of the latter 
may be reduced only slightly by lowering the insonation frequency, usually to 
1.8–2.0 MHz, in the case of poor bone windows. Semiquantitative visual 
grading is less reliable (Walter et al., 2014b). 
Because of potential interference with echosignals originating from 
structures of the basal cisterns, the echogenicity of the SN is assessed only 
ipsilaterally to insonation. Therefore, TCS of SN needs to be performed from 
both sides. The clearest, most compact view of the SN echogenic signals is 
visualized by very slight probe movements. The axial midbrain transection 
showing the echosignals of the ipsilateral SN in its largest extension is localized 
by slight tilting of the probe. If the SN is seen very clearly, the image is frozen 
immediately. After choosing the optimum frame using the cine mode if 
necessary, the midbrain is zoomed out two- to threefold. The SN echogenic 
signals are surrounded manually by the cursor using the trackball, resulting in 
automatic calculation of the echogenic area. 
Quality criterion of the adequate visualization of the SN is when the 
echosignals of the SN are displayed at a typical anatomic location in the crus 
mesencephali and are well separated from the echosignals of the red nucleus 
and basal cisterns (Walter et al., 2014). 
Several approaches for automated SN detection and the quantification of its 
echogenicity have been published recently, including principal component 
analysis based artificial neural networks (Blahuta et al., 2013), active contour 
segmentation algorithms (Sakalauskas et al., 2013), invariant scale blob 
detection (Walter et al., 2014), and 3-dimensional SN detection (volumetry) 
based on random forests. Novel technologies aiming to reduce investigator 
dependency, such as measuring the echointensity of the SN relative to the 
surrounding parenchyma, volumetry, semi-automated SN detection, or complex 
mathematical echo-signal analysis, have either failed or are not yet ready for 
clinical application (Chen et al., 2012; Walter et al., 2014).  
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The normal ranges need to be established for each ultrasound system because 
of some potential investigator dependency for each lab (Walter et al., 2013). 
 
Figure 3. Visualization of midbrain SN+  
SN+ dex (right side SN+ area, what was surrounded manually with the cursor and the 
planimetric area (cm2 was calculated automatically; 0. 36 cm2) and SN+ sin (left side 
SN+, 0.32 cm2)  
 
 
2.8.4. Visualization and assessment of brainstem raphe echogenicity 
The assessment of the raphe is anatomically restricted to the lower midbrain 
with obligatory simultaneous visualization of the red nucleus. In early studies 
(Becker et al., 1995) 4 grades of echogenicity were applied as follows: (1) raphe 
not visible; (2) reduced or interrupted echogenicity; (3) normal, i.e. continuous 
line with an echogenicity similar to that of red nucleus; (4) increased 
echogenicity. The current consensus guideline recommends the discrimination 
of only two grades (normal vs reduced echogenicity, Figure. 4) (Walter et al., 
2014). Raphe echogenicity should only be classified as reduced if TCS from 
both sides shows reduced echogenicity under adequate imaging conditions. 
Occasionally a healthy subject exhibits marked echogenicity of the red nucleus 





even though the diagnostic implcations are unclear. Quality criterion of 
adequate assessability of the red nucleus: basal cisterns, SN and midline 
structures (raphe, aqueduct) are clearly displayed. 




2.8.5. TCS limitation 
The first limitations of TCS in the evaluation of SN+ is the dependence of 
image quality on both the sonographer’s experience and the quality of the bone 
window. In European populations, 4–15% of participates were found to have an 
insufficient temporal window (Mehnert et al., 2010; Dun-Hui, Li et al. 2016). 
However, the value rises to 15–60% in Asian populations (Izawa, et al.,2012; 
Dun-Hui, Li et al. 2016). This high recording failure rate in TCS application 
would mostly affect patients of advanced age with female gender (Okawa, et al. 
2007) or patients with a small temporal window seen in Asian populations 
(Okawa et al., 2007). Sonographers without TCS experience could have 
problems with correctly imaging the SN. One of the possible reasons for worse 
visibility in female patients is osteoporosis, it was found in a prospective study 
that among the women bone mineral density was significantly lower in the PD 





more advanced disease (Raglione et al. 2011). Some new MRI–TCS fusion 
imaging with virtual navigation technology could be helpful in this case 
(Školoudík et al. 2014). Recently, high-resolution ultrasound systems with 
standardized settings or with automated segmentation technique were reported 
to reduce inter-observer and intra-observer variability (Sakalauskas et al., 
2013), which may help improve TCS image quality and decrease the incidence 
of insufficient temporal window. Moreover, a novel approach using transcranial 
B-mode sonography, a 3-D ultrasound platform, was shown to be technically 
feasible and less dependent on sonographer experience or good bone windows 
(Plate,et al. 2012). These innovations and developments in ultrasound systems 
may effectively improve the application value and diagnostic accuracy of TCS. 
 
 
2.9. Summary of the literature review 
PD is the most common movement disorder. Clinical diagnosis of PD is 
reasonably easy in most cases but the distinction between different variants of 
parkinsonism may be difficult in early stages. TCS is a relatively young method 
which has evolved as an important diagnostic tool for not only PD diagnosis but 
also for atypical parkinsonian syndromes. SN+ is the hallmark for PD but how 
valid and helpful is it in clinical diagnosis of PD in a different community is the 
question. It’s important to assess the validity of the SN+ in the PD group and in 
the healthy controls, because TCS as a method is easy applicable, noninvasive 
and easily available in everyday practice in Estonia. Yet each lab has to use its 
own cutoff value derived from the ultrasound system and assessment method 
used. Several studies showed that TCS is a well reproductible method and has 
high specificity for the diagnosis of PD. 
Depression is a part of PD itself, resulting from changes in the chemistry of 
the brain. In my study, I decided to evaluate the role of BR in the occurrence or 
non-occurrence of the symptoms of depression and whether this can be assessed 
with TCS. 
I know that age is the best PD progression marker but we need to study how 
SN+ reacts in different situations. Not only in longitudinal studies but also we 
need information from cross-sectional studies. It is not fully clear what the 
development of SN+ will be in the course of the disease of a patient. Most of 
the studies have confirmed that SN+ is a stable biomarker. Longitudinal studies 
would definitely provide a better overview of the stability of SN+, but it was 
necessary to establish whether different factors impact the stability of SN+ and 




3. AIMS OF THE STUDY 
The primary objectives of the current study were: 
 
1. To investigate the diagnostic accuracy for validation of SN + as assessed by 
TCS in a large sample of patients with PD in Estonia. 
 
2. To describe the prevalence and severity of depressive symptoms in PD, and 
to analyze associations between brainstem raphe echogenicity and 
depressive symptoms of patients with PD compared to age- and education-
matched healthy (non-PD) controls. 
 
3. To analyze whether SN+ values are different on sides mirroring the asym-




4. PATIENTS AND METHODS 
4.1. Study population and sample design 
The study was prospectively conducted from January 2010 to January 2019 
using a sample of 300 patients (aged 30–80 years), which accounts for 10% of 
PD patients in Estonia with PD according to the QSBB diagnostic criteria 
(Hughes et al., 1992; Lees et al., 2009). Patients were consecutively recruited 
from the Outpatient Clinic of the Department of Neurology of the East Tallinn 
Central Hospital and the Neurological Clinic of Tartu University with the same 
ultrasound maschine by one sonographer. Exclusion criteria included con-
comitant neurologic disorders affecting the central nervous system, other brain 
abnormalities and that made the diagnosis of PD unlikely. Therefore, all 
patients with PD underwent either CT or MRI before study enrollment. The 
control group consisted of 200 individuals who were similar in age and gender 
to the PD group with no history of central nervous system diseases. The control 
group comprised 141 individuals from older male and female choirs, 29 clinic 
staff members, and 30 neurologic patients with peripheral nerve disorders or 
musculoskeletal diseases or their family members. The control group did not 
undergo computed tomography or magnetic resonance imaging. From a total of 
500 participants, 66 (13.2%) were exclude from the analysis because of 
insufficient temporal acoustic bone windows for TCS inspection.Thus, the study 
groups consisted of 266 patients with PD (88.7%) and 168 (84%) controls. 
The study was approved by the Ethical Committee on Human Research of 
Tartu University. All participants signed a written informed consent form 
according to the Declaration of Helsinki. 
 
 
4.2. Clinical examination 
Patients underwent general neurological examination. The patients’ history was 
assessed by a neurologist who was experienced in the field of neurodegene-
rative disorders. The neurological rating scales and other clinical tests were 
performed by 2 different neurologists who were blinded to TCS data. Patients 
with PD were taking their optimized dopaminergic treatment on the day of 
clinical evaluations. All investigations were performed within a single day. 
Disease severity was scored using the Movement Disorders Society Unified 
Parkinson’s Disease Rating Scale section III (MDS-UPDRS III), and HYS 
(Hoehn et al., 1967). To define the severity of PD-related motor impairment, the 
HYS and MDS-UPDRS III (Goetz., et al., 2012) were applied. Hyposmia was 
evaluated using the Sniffin’ Sticks 12 smell test (Heinrich Burghart GmbH, 
Wedel, Germany). MDS-UPDRS III is the most widely used standardized scale 
to assess motor symptoms of parkinsonism. It is designed to monitor PD 
Shwab-England Scale (SE). HYS provides a global assessment of disease 
 
30 
severity, based on clinical findings and functional disability. The scale includes 
stages from 0 (no signs) to 5 (wheelchair-bound or bedridden unless aided) to 
indicate the relative level of disability.  
In order to examine the cognitive function, the Mini-Mental State Exami-
nation (MMSE) was used (Folstein et al.,1975). Scores of 25–30 out of 30 are 
considered normal. Patients were assessed in the ‘on’ state and their medication 
dose was recorded as the levodopa equivalent dose (LDED) using the algorithm 
adapted from Brodsky and colleagues (Goetz et al., 2012). 
 
 
4.2.1. Behavioral assessment 
Depressive symptom severity was measured by the Beck Depression Inventory 
(BDI) (Beck et al., 1961). The BDI is regarded to be a valid, reliable, and 
responsive instrument to assess the severity of depressive symptoms in PD 
(Schrag al., 2007). Symptom severity based on BDI scores was categorized as 
being within normal limits (0–9), indicating mild (10–16) or severe depressive 
symptoms (>16). 
Schwab and England Activities of Daily Living Scale (SE) is a means of 
assessing a person’s ability to perform daily activities in terms of speed and 
independence, with 100% indicating total independence and 0%, indicating a 
state of a complete dependence (Schwab al.,1969). 
Parkinson’s Disease Questionnaire (PDQ-39) (Jenkinson et al., 1997) was 
used to assess the health-related quality of life of PD patients. The PDQ-39 is a 
self-administered questionnaire comprising of 39 questions related to eight key 
areas of health and daily activities, including both motor and non-motor 
disturbances in quality of life. It is scored on a scale of 0–100, with lower scores 
indicating better health and higher scores showing a worse quality of life. 
 
 
4.3. TCS methodology 
TCS examination was performed with a ultrasound machine Logic7 (General 
Electric, Healthcare, Waukesha, WI, USA) with a 1.8–3.6 MHz transducer 
(General Electric, Healthcare, Waukesha, WI, USA) which is also used for 
transcranial duplex sonography. The ultrasound examination was performed 
according to the international consensus guidelines (Walter et al., 2007a,b; 
Weise et al., 2009). The best visualization of the brain parenchyma was achieved 
when the imaging depth was set to 14–15 cm and the dynamic range between 
40 and 60 dB. Image brightness was adjusted as needed (used the ‘Gain’or 
‘Time Gain Compensation’ button of the device. The best resolution was 
achieved at a distance of about 5–9 cm from the probe which is called the focal 
zone. Under optimal conditions, contemporary systems achieved an axial 
(horizontal) resolution of up to 0.7 mm in the focal zone. All TCS examinations 
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were performed by one experienced sonographer (thesis author) before clinical 
investigations. 
The sonographer was unable to see the patient information, e.g. the onset of 
first clinical symptoms and the time of PD diagnosis. Ultrasound examination 
was performed in a darkened room. B-mode gain and lateral gain control were 
used to adapt image brightness. The mesencephalic brainstem was identifiable 
due to its butterfly shape. The image was frozen at the largest extension of SN. 
The SN+ at the anatomical site of the SN was marked and measured on the 
frozen image. The area of SN+ was encircled with the cursor and the size of the 
indicated area was calculated automatically (cm²). The measurement of the 
largest scope of SN was performed 3 times for both sides using gain/brightness 
and the mean value was calculated. The brainstem raphe imaging process was 
performed secondarily. The mesencephalic brainstem was identified by its cha-
racteristic butterfly shape (Figure 2). The image was frozen when the brainstem 
raphe was visible at its largest extension. After image freezing, the brainstem 
was zoomed two- to threefold. Echogenicity of the brainstem raphe was rated 
semiquantitatively, using a 3-point scale (2 – not visible; 1 – partially visible; 
0 – fully visible, highly echogenic continuous line) (Bouwmans et al., 2016). To 
make sure that the best possible assessment of the brainstem raphe could be 
obtained, raphe echogenicity should only be classified as reduced if TCS from 
both sides shows reduced echogenicity under adequate imaging conditions. 
 
 
4.4. Statistical methodology 
All the studies included in this thesis were observational cross-sectional studies 
for which a large PD sample derived from two Estonian PD medical centers was 
used. The study data was analyzed with the statistical programs SPSS, MedCalc 
and open software R (version 2.15.0). Descriptive data were reported as the 
mean and the standard deviation for numeric data and frequency (percent) for 
categorical data. 
Study I: Continuous data were expressed as the mean value and median 
value while identifying the cutoff value for different measurements. As the 
mean is more affected by the outliers, the median value of the measurements 
was also used. The logarithmic transformation was applied to SN+ value of the 
multiple measurements. Data for the area of SN+ were not normally distributed 
while evaluated by a quantile-quantile plot. For group comparisons of 
categorical data, a χ2 test was performed. An independent paired t-test was used 
to compare numeric variables between the groups. For group comparisons the 
Mann–Whitney test was used. The cutoff value for SN+ was established by 
receiver operating curve (ROC) analysis, comparing patients with PD with 
controls. In addition, the 75th and 90th percentiles were defined for the control 
group. After determining the cutoff value for the different measurements, the 
following parameters were calculated: sensitivity, specificity, area under the 
curve (AUC), negative and positive predictive values, test accuracy, and the 
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number of false positive and false negative results. Furthermore, characteristics 
from different ROC curves were compared by a pair-wise comparison to 
examine whether 3-times repetition of SN assessment resulted in higher 
diagnostic accuracy than a single registration of SN+, while p < 0.05 was used 
as the criterion for statistical significance. To evaluate the normal distribution of 
the variable, the Kolmogorov–Smirnov test was used. 
Study II: Depressive symptoms analysis with respect to PD patients and 
non-PD controls. Between two groups analysis with respect to covariates was 
performed with the Mann–Whitney test and MANCOVA. The assessment 
scores were compared with regards to the depressive symptom severity levels. 
The correlations of demographic values, scores on clinical rating scales, 
brainstem raphe echogenicity levels and depressive symptoms were performed 
using the Spearman’s rank correlation and partial correlation. 
Study III: ‘Onset SN+’ was defined as SN+ measured contralaterally to the 
side of the body that first manifested PD related motor disturbance. Conversely, 
the ‘non-onset SN+’ was measured ipsilaterally to the body side first experiencing 
PD motor symptoms. As regards the controls, this differentiation was not 
applied. Moreover, the average of both sides was calculated. Characteristics of 
onset and non-onset SN+ values were compared with the independent paired  
t-test, as these data were normally distributed (Kolmogorov–Smirnov test 
p > 0.05). To explain the changes in SN+, the correlation analysis was performed 
using candidate clinical parameters, and the Spearman coefficient was 
calcuated. For evaluating the association between the size of SN+ (onset vs non-
onset side) with various clinical markers, only the PD group (266 patients) was 
included, because only in that group could the laterality of SN side be defined. 
Furthermore, the relationship between SN+ and significantly correlating clinical 
parameters was further characterized by the multiple linear regression analysis 
with the patient’s age at study time, HYS (grading PD severity), and MDS-
UPDRS III (measuring PD motor symptoms) as independent variables, and 
onset and non-onset SN+ as dependent variables. For the evaluation of a 
potential age effect on SN+ the healthy group was also included, assuming that 
age might be also a risk factor for developing the severity symptoms of PD. 
Both correlations were compared with the age to find out whether age or 
severity of PD symptoms were the main drivers of the SN+. 
To determine whether SN onset side or the larger area is more relevant for 
evaluating PD patients, both correlations of the dependent samples were 





5.1. Study population 
The study groups consisted of 266 patients with PD and 168 controls, because 
of an insufficient temporal acoustic bone window for TCS inspection, 66 
individuals (34 with PD, 32 healthy controls) were excluded from the analysis. 
The excluded subjects did not differ in mean age (69.8 vs 70.3) from the rest of 
the cohort. Among PD patients, an insufficient bone window was more 
noticeable in female patients than in males (25% vs 9%, p=0.96). The sex 
difference regarding bone window insufficiency was not statistically significant 
in healthy controls (12% of females, 6% of males). The age range of the patient 
group was 37–87, while the healthy control group was composed of 168 
subjects between the ages of 50 and 86 (Table 2.). 
 







Age at evaluation, y 69.3±9.19 70.4±7.79 0.56 
Male, n (%) 140 (52.6) 88 (52.4) 0.96 
Education, y 12.8 (2.85) 12.4 (2.52) 0.17 
Disease duration, y 6.1±5.21 NA  
Neurological assessment 
MDS-UPDRS III ( “on” state) 31.23±14.58 3.0±2.24 <0.001 
HYS 2.66±0.80 NA  
1 28 (10.5)   
2 88 (33.1)   
3 113 (42.5)   
4 35 (13.2)   
5 2 (0.8)   
Behavioral assessment 
BDI 14.6 (8.3) 11.9 (6.0) <0.001 
MMSE 27.91 (2.84) 29.2 (1.31) <0.001 
Schwab-England 77.2 (14.60) NA  
PDQ-39 29.2 (17.47) NA  
Medication 
LDED, mg 418±366 NA  
Antidepressants, n  20 (7.5) NA  
Neuroleptics, n 5 (1.9) NA  
 
Data are presented as mean ± standard deviation (SD) and number (percent) where 
applicable. 
MDS-UPDRS III indicates Movement Disorders Society Unified Parkinson’s Disease 
Rating Scale, motor part; HYS (Hoehn Yahr Stage), BDI (Beck Depression Inventory); 
MMSE (Mini-Mental State Examination; PDQ-39 (Parkinson’s Disease Questionnaire) 
LDED – levodopa-equivalent daily dose; NA – not applicable, P – p value. 
 
34 
5.2. Clinical examination 
Based on the history given by the subjects, duration of PD ranged from 1 to 25 
years (mean duration 6.1±5.21 years). The average total MDS-UPDRS III 
(Motor Examination part III) on state in the PD group was 31.23 ± 15.1 and in 
the controls 3.0±2.2. Sniffin’ Sticks test result in the PD group was 5.6±0.19 
and 8.6±0.18 in the controls. 
The HYS was in the PD group 2.66±0.8. The levodopa equivalent daily dose 
in PD patients was 418 ± 366 mg. Only a small proportion of PD patients were 
using antidepressants at assessment time (n=20; 7.5%). Of those, 6.8% with 
mild and 13.7% with severe depressive symptoms were using antidepressants. 
In the PD group, 38.7% and 35.7% of patients had mild and severe depressive 
symptoms, respectively. In the control group, 26.8% and 28.6% were classified 
as having mild and severe depressive symptoms, respectively. The percentage 
of depressive symptoms in controls was significantly lower than in the PD 
group (p<0.001). The clinical profile of PD patients from no depressive 
symptoms to mild or severe depressive symptoms is based on BDI scores 
(Table 2).  
PD patients who were using antidepressants had significantly more depressive 




5.3. TCS results 
5.3.1. Specificity and sensitivity of TCS in the study cohort 
The study examined the significance of single and repetitive measurements of 
SN area in the diagnostic accuracy of PD. The single assessment cutoff value 
using the GE LOGIQ 7 system was 0.21 cm2, with a sensitivity of 93.2% and 
specificity of 85.1% (Table 3). The rate of false-positives was 14.9% and the 
rate of false-negatives was 6.8%. 
Optimal cutoffs were defined for the calculated multi-mean and multi-median 
values in order to establish whether an average of 3 repeated measurements of the 
echogenic SN area increased the diagnostic accuracy. The multi-mean cutoff 
value was 0.23 cm2 (AUC, 0.962; p<0.0001), corresponding to a sensitivity of 
88.7% and a specificity of 92.2%. The multi-median cutoff value was 0.23 cm2 
(AUC, 0.963; p<0.0001), with a sensitivity of 88.7% and a specificity of 90.5%. 
False-negative rate had a tendency to be lower in the case of multiple 
assessments compared with a single assessment. There was a high correlation 
between the results based on different measurement strategies. The coefficient 
of intraclass correlation was 0.991 for the single measurement versus multi-
median and in the case of multi-median versus multi-mean the coefficient was 
0.999. With regard to specificity, our data revealed that the multiple-assessment 
strategy was superior to the single assessment (p=0.0021). The statistical 
comparison of the multi-mean assessment with the multi-median assessment did 







































































































































































































































































































































































































































5.3.2. Optimal cutoff vs 75th and 90th percentile scores 
As statistically there was no difference between the SN+ multi-median and 
multi-mean values, in order to define the 75th and 90th percentiles in controls, 
only median values were used for the multiple assessments. The cutoff value for 
the 75th percentile was 0.18 cm2 (AUC, 0.964; p<0.0001), whereas for the 90th 
percentile it was 0.22 cm2 (AUC, 0.964; p<0.0001; Table 3). 
 
 
5.3.3. Severity levels of depressive symptoms in PD patients  
The clinical profile of PD patients with no, mild and severe depressive 
symptoms based on BDI scores is presented in Table 4. Only a small sample of 
PD patients were using antidepressants at assessment time (n=20). Of those, 
6.8% with mild and 13.7% with severe depressive symptoms were using 
antidepressants. PD patients who were using antidepressants had significantly 


















UPDRS I 5.3 (3.8) 7.9 (4.5) 11.3 (5.6) 0.002a, <0.001b,c 
UPDRS II 7.7 (4.9) 10.7 (6.0) 15.2 (6.3) 0.01a, <0.001b,c 
UPDRS III 24.4 (13.2) 29.2 (12.3) 38.3 (14.9) 0.076a, <0.001b,c 
Hoehn and Yahr 2.3 (0.7) 2.5 (0.7) 3.1 (0.7) 0.089a, <0.001b,c 
Schwab-England 87.5 (9.4) 79.3 (11.3) 67.6 (15.0) < 0.001a,b,c 
MMSE 28.5 (2.5) 28.2 (2.3) 27.2 (3.4) 1.0a, 0.025b, 0.005c 
BDI 6.0 (2.6) 12.3 (1.9) 23.4 (7.1) <0.001a,b,c 
PDQ-39 25.4 (20.1) 24.9 (13.2) 36.6 (17.3) 1.0a, <0.001b,c 
Results are given as mean standard deviation (SD): 
a within normal limits vs. minor depressive symptoms; 
b minor vs. major depressive symptoms; 
c major depressive symptoms vs. within normal limits. 
 
UPDRS I indicates Movement Disorders Society Unified Parkinson’s Disease 
Rating Scale, part I; UPDRS II indicates Movement Disorders Society Unified 
Parkinson’s Disease Rating Scale, part II; UPDRS III indicates Movement 
Disorders Society Unified Parkinson’s Disease Rating Scale, part III; HYS 
(Hoehn Yahr Stage), BDI (The Beck Depression Inventory); MMSE (The Mini-
Mental State Examination; PDQ-39 (The Parkinson’s Disease Questionnaire) 
LDED – levodopa-equivalent daily dose 
 
 
5.3.4. Brainstem raphe echogenicity 
In both PD patients and controls, higher BDI values were associated with 
reduced brainstem raphe echogenicity. In the PD group, there were statistically 
significant differences (p<0.001) between the patients’ BDI scores of all three 
brainstem raphe visibility levels. In the control group, individuals with fully and 
partially visible brainstem raphe exhibited considerably fewer depressive 
symptoms than the ones whose brainstem raphe was not visible (p<0.001). As 
for the between-group (PD vs non-PD), significant differences in depressive 
symptoms were only evident in the ‘partially visible brainstem raphe’ subgroup 
(p<0.001). Based on the multivariate analysis, the effect of brainstem raphe 
echogenicity on depressive symptom severity scores in the patient group 
remained significant even after accounting for the HYS as a covariate (f1.5=15.1, 
p<0.001) (Table 5). 
A direct correlation was discovered between brainstem raphe echogenicity 
and age (Spearman’s rank correlation, r=0.132, p=0.006). Mean echogenicity 
scores in women and men did not seem to differ to that extent (women: 1.27 












































































































































































































































































































































































































































































































































































































































































































































































































































Higher BDI scores indicating severe depressive symptoms had a direct correla-
tion not only with older age, but also longer disease duration, loss of inde-
pendence in daily activities, more noticeable motor dysfunction and cognitive 
impairment (see Table 2 for details). Except for the MMSE, demographic and 
clinical variables indicating more severe disease stages were also directly 
associated with brainstem raphe echogenicity. Moreover, brainstem raphe 
echogenicity was significantly correlated with the BDI total score in both the 
PD (r=0.59, p<0.001) and control groups (n=0.66, p<0.001). Using partial 
correlation analysis and controlling for age, PD duration and HYS, the direct 
relationship between BDI score and raphe echogenicity level remained 
significant (r=0.5, p <0.001). 
 
5.3.5. SN+ values are different on the respective sides mirroring  
the asymmetric character of Parkinson’s disease group and  
in the control group 
The average mean SN+ values of both sides were considerably higher in the PD 
group (0.33±0.10 cm2) than in the control group (0.16±0.05 cm2, p<0.001) 
(Table 2). The size of the left and right side SN+ (left side 0.35±0.11cm2; right 
side: 0.36±0.13cm2, p=0.31) were not statistically different among PD patients. 
Yet it was discovered that onset SN+ (0.35±0.12 cm2) of the contralateral SN of 
the initial motor symptoms side appeared to be on average 17.6% larger than 
non-onset SN+ in PD patients (mean 0.30±0.10 cm2, paired t test, p<0.00, 
Figure 6)  
 
Figure 6. Sonographic image of substantia nigra hyperechogenicity (SN+) in PD 
patient. 
Sonographic image of corresponding midbrain axial sections in PD patient. The 
butterfly-shaped midbrain was encircled for better visualization. Marked bilateral SN+ 
of the subject was encircled for computerized measurement. SN+ onset 0.31 cm2 and 





5.3.6. The effect of clinical and demographic  
parameters on SN+ in PD patients and healthy controls 
A significant negative correlation was found between onset SN+ and PD 
patient’s age at study time (rs = –0.199, p<0.01) and the HYS (rs = –0.162, 
p<0.01), and MDS-UPDRS III score (rs = –0.139, p < 0.05) (Table 6). No signi-
ficant correlation between non-onset SN+ side and any of the assessed clinical 
parameters was found. Multiple linear regression analysis with predictors 
(1) age at study time, (2) HYS and (3) MDS UPDRS III were used with the 
result of a significant model (p=0.0015). We discovered that the age at study 
time had a noticeable correlation with a change in the area of onset SN+ 
(p=0.017). 
The regression model of PD patients showed that the age at study time and 
HYS have a negative correlation with the size of onset SN+. If the model 
included the non-onset SN+ as dependent variable with the same predictor 
variables, the overall model fit indicated an unstable prediction model (p=0.17).  
 
Table 6. Spearman correlation coefficients (rs) of SN+ for the onset and non onset side 
and clinical markers in PD (n=266). 
  Onset SN+ 
Correlation coefficient (r) 
Non onset SN+ 
Correlationcoefficient (r) 
Age at study time –0.199** –0.076 
HYS –0.162** –0.077 
LDED† –0.139* –0.031 
MDS UPDRS III –0.132* –0.068 
*p<0.05; **p<0.01 
HYS – Hoehn Yahr Stage 
LDED – levodopa equivalent daily dose  
MDS UPDRS III – the Movement Disorders Society Unified Parkinson’s Disease 
Rating Scale part III 
† Correlations for LDED are reported without 0 values 
 
Subsequently, the relationship between age and SN+ was investigated, including 
the healthy controls. It was discovered that whereas SN+ in healthy controls 
increases with age (p=0.0004), in PD patients SN+ contralateral to the initially 
affected side decreases (p=0.0049) (Figure 7). The data suggest that the 
relationship with age and SN+ depends on whether the individual has PD. The 
higher age is associated with an increase in SN+ in healthy individuals 
(p<0.0001), while in PD patients it showed a decrease in onset SN+ (p=0.0049). 
Among the patients with visible SN (n=266) there were 67 patients out of 266 
(25% of the cohort) who did NOT have a higher onset SN area and for 9 







Figure 7. The effect of age on SN+ in PD symptom onset and healthy controls. The 
higher age is associated with an increase in SN+ in healthy individuals (p<0.0001), 






The present study was the first research project using TCS investigation in the 
Estonian cohort of Parkinson’s disease and healthy subjects.  
Although TCS for movement disorders has been in use since 1995, we 
performed the first investigations of our patients in Estonia in 2008. By 2010 
we had enough experience to start investigating PD patients on the scientific 
level.  
Clinically, the most striking feature of TCS in its application in PD is the 
visualization of the SN with its different sizes and echogenicities. It has been 
abundantly shown that individuals with PD have an increased area of 
hyperechogenicity at the anatomical site of the SN compared to controls (Walter 
et al., 2004; Walter et al., 2007a), a finding unique for TCS. I investigated 266 
Estonian PD patients and 168 healthy controls whose age and education 
matched the patient group.  
The main limitation of the TCS is the lack of bone window in about 10% of 
the Caucasian population (Gaenslen et al., 2008; Walter et al. 2007a). This rate 
seems to be increasing with advancing age and may reach to up to 25% 
especially in elderly women (Walter et al. 2007a). It has been speculated that 
osteoporosis may play a role in the deterioration leading to an increased 
dispersion of the ultrasound beam. On the other hand, in Asian subjects, an 
insufficiency of temporal bone window occurs in 15 to 60 percent of patients 
(Kim et al., 2007; Okawa et al., 2007).  
Our results correspond to the findings of other studies. Although an 
impenetrable temporal bone window is a clear limitation of the method, we 
showed that the percentage of individuals with an insufficient bone window 
among Estonians (13.2% and 25% of female PD patients) is similar to the rate 
found in other European countries (Berg et al., 2008; Školoudík et al. 2010). 
Higher failure rates for transcranial sonography due to an insufficient bone 
window have been reported among Japanese, Taiwanese, South American, 
Australian, and South Korean populations. These differences may be caused by 
lower bone mineral density in these populations due to lower dietary calcium 
intake compared with Filipino and white populations (Okawa et al., 2007; Go et 
al., 2012; Kim et al., 2007; Fernandes et al. 2011). 
One possible reason for worse visibility in female patients is osteoporosis 
(Raglione et al., 2011), though we did not study the reason for differences in 
bone windows specifically. In a prospective study, it was found that among 
women bone mineral density was significantly lower in the PD patients than in 
the controls, and the decrease in bone window visibility was greater in the 
subgroup with more advanced disease (Raglione et al., 2011). 
The aims of our study were: 
1)  To find an optimal SN+ cut off for our Estonian PD patients to continue 
research in this field, and to compare the SN+ diagnostic accuracy of PD 




2) To describe the prevalence and severity of depressive symptoms in PD, as 
well as to analyze possible associations between BR echogenicity and 
depressive symptoms in an Estonian sample of patients with PD compared to 
age- and education-matched healthy (non-PD) controls. 
3) To study associations of SN echogenicity values measured in daily clinical 
practice with clinical or demographic charactreristics of PD patients. 
 
 
6.1. Diagnostic accuracy of SN+ 
Each lab has to use its own cutoff value derived from the ultrasound system and 
assessment method used (Bowmans et al., 2013). For example, for the Sonoline 
Elegra system (Siemens AG, Munich, Germany) and the MyLab25 Gold system 
(Esaote SpA, Genoa, Italy), a cutoff value of 0.20 cm2 has been suggested in 
German and Filipino populations (Berg et al., 1999; Go et al., 2012). For the GE 
LOGIQ 7 system, an even higher cutoff value (0.24 cm2) for PD diagnosis has 
been reported in Austria and in Germany (Stockner et al., 2007; Van de Loo et 
al., 2010). 
The first goal of this study was to validate SN+ in a large Estonian PD 
patient cohort and healthy controls. Our results correspond to the findings of 
other studies. The single assessment cutoff value using the GE LOGIQ 7 system 
was 0.21 cm2, with a sensitivity of 93.2% and specificity of 85.1%. The rate of 
an enlarged SN area (false positive) was 14.9% and the rate of exhibited SN 
areas (false-negative) was 6.8%. The multi-mean cutoff value was 0.23 cm2, 
corresponding to a sensitivity of 88.7% and a specificity of 92.2%. The multi-
median cutoff value was 0.23 cm2 (AUC, 0.963; p < 0.0001), with a sensitivity 
of 88.7% and a specificity of 90.5%. The false-negative rate was lower in 
multiple assessments compared to a single measurement. There was a high 
concordance between the results based on different measurement strategies: the 
coefficient of intraclass correlation was 0.991 for the single versus multi-
median measurement, and in the case of multi-median compared to multi-mean 
the coefficient was 0.999.  
Our study’s cutoff value using the GE LOGIQ 7 system was ≥0.23 cm2, the 
same cutoff value that has previously been calculated in other studies with the 
same ultrasound device, confirming the validity of the method itself (Stockner, 
et al., 2007; 2012). 
The sensitivity and specificity of SN+ are still a matter of debate. The 
sensitivity and specificity for the diagnosis of PD based on the detection of SN+ 
by image analysis were 87% and 92%, respectively (Školoudík et al., 2013). In 
another study, applying 3-dimensional quantification of SN echogenicity 
sensitivity and specificity for the diagnosis of PD of up to 91% and 73% were 
reported (Plate et al., 2012). 
The normal ranges need to be established for each different US-S and 
because of some potential investigator dependency also for each different lab. In 




is compared to that of a representative control group (Van de Loo et al., 2010). 
Moreover, variations in cutoff values are also caused by the fact that different 
algorithms have been applied to define the cutoff value for SN+. Most studies 
calculated the 75th or 90th percentile of the enlarged SN area in a reference 
group as the critical value for SN+ (Bouwmans et al., 2013; Mahlknecht et al., 
2013). In other studies, the cutoff value represented the first or second standard 
deviation below the population mean value in control partipants (Berg et al., 
2010; Mahlknecht et al., 2013; Walter et al., 2002). To rate SN echogenicity in 
an individual as normal or increased (SN+), the 75th and 90th percentile of 
measures in the normal population were used as by Berg (Berg et al., 2008). 
The larger of bilaterally measured SN+ sizes is used for classification as 
follows: (1) normal echogenic: measured area is below the 75th percentile; 
(2) moderately hyperechogenic: measured area is between the 75th and the 90th 
percentile; (3) markedly hyperechogenic: measured area is above the 90th 
percentile. 
We use of 75th and 90th percentiles of controls as an option to find the 
optimal SN+ cutoff, as statistically there was no difference between the SN 
multi-median and multi-mean values in order to define the 75th and 90th 
percentiles in controls; only median values were used for the multiple 
assessments. The cutoff value for the 75th percentile was 0.18 cm2, whereas for 
the 90th percentile it was 0.22 cm2. 
Although it makes little sense statistically as it only fixes the specificity at 
75th or 90th, I suggest another option: increasing the number of so-called 
categories, using two cutoffs, cutoff A and cutoff B, correspondingly. Thus, if 
the measurement result is X and X > B, the person is ill (specificity 100% or 
almost 100%), but if X < A, the person almost certainly has no illness 
(sensitivity 100%), but if A < X < B, additional investigations are needed.  
I created a model ‘what is your probability to become ill from a PD?’ where 
X is an average measurement result, and A is SN+ with 100% sensitivity, and B 
is SN+ with 100% specificity. According to the formula, A is 0.14 cm2 and B is 
0.34 cm2 in our group, and in such a case we can conclude that if the 
measurement result is 0.34 or higher, the person is ill (specificity 100%), and if 
the measurement is 0.14 or lower, the person does not have the illness 
(sensitivity 100%). This is a rather simple calculation, but helpful for the 
diagnosis of PD in clinical practice when the measurement result is in the range 
between 0.14 cm2 and 0.34 cm2. Still, additional investigations are needed on 
other progressive parkinsonian disorders (MSA, PSP, CBD). In cases of MSA, 
SN+ occurred in 15% cases (Behnke, 2005; Fujita, 2016; Okawa, 2007; Walter, 
2003), but in contrast to PD, SN+ seems far less frequent in PSP with an 
average rate of 28% (Berg, 2018) In CBD patients had SN+ mean prevalence 
67% (Sadowski, 2015). 
This study had methodological limitations. Although the person performing 
transcranial sonography had no knowledge of the exact state and progression of 
the disease, he was not blinded to the diagnosis of PD. Therefore, the clinical 




In summary, the importance of this study in many areas. On the basis of our 
subjects we can say that the optimal cutoff diagnostical value 0.23 cm2 is found 
on the basis of several consecutive measurements. The results of our study 
revealed the significance of repetitive measurements of the SN area for the 
diagnostic accuracy of PD: we verified that 3 repetitive measurements of the SN 
echogenicity on TCS increase the diagnostic accuracy of the disease. 
 
 
6.2. The associations between brainstem raphe 
echogenicity and depressive symptoms  
in the Estonian cohort 
In the present study, 72.3% of patients with PD with severe depressive 
symptoms (n = 68), and 89.6% of controls with severe depressive symptoms 
(n = 43) both showed significant BR hypoechogenicity whereby the raphe was 
completely not visible. 
The present study demonstrated that depressive symptoms severity is an 
important factor modulating the clinical aspects of PD. We showed a direct 
correlation between brainstem raphe echogenicity and BDI score in PD patients 
and healthy controls, but with considerably greater reduction of brainstem raphe 
echogenicity in PD patients with depressive symptoms in comparison with non-
PD controls with the same symptoms. However, the percentage of people 
exhibiting severe depressive symptoms and hypoechogenic brainstem raphe was 
higher among the controls. This phenomenon could be explained by the fact that 
the neurodegenerative process in PD has an effect on the brainstem raphe in the 
majority of people whose depressive symptoms are above normal levels, 
whereas in the non-PD control group, the higher occurence of self-reported 
depressive symptoms may be explained by a well-preserved awareness of 
mental health problems. TCS can be used to assess brainstem raphe as an 
important marker for depressive symptom severity in both PD patients and 
healthy individuals. As depression has a major effect on the quality of life, 
sufficient therapy is mandatory.  
In the current study, there was also a direct association between depressive 
symptom severity and hypoechogenic brainstem raphe in PD patients when 
taking into consideration the patients’ age, disease duration and HYS. It is 
interesting to note that partially reduced visibility of the brainstem raphe was 
evident in 58.7% of controls with a normal BDI score and as high as 64.4% of 
controls suffering from mild depressive symptoms. In the PD group, the 
respective proportions were 23.5 and 53.4. Taken together, signs of mesen-
cephalic brain pathology may be a radiological marker for depressive symptom 
severity in both patients and controls. Our findings are in concordance with 
previous reports that brainstem raphe echogenicity is altered in individuals with 
depression (Becker et al., 1994; Walter et al., 2007). The level of affective 




Decreased echogenicity of the mesencephalic raphe has been found in 40 to 60 
percent of patients with PD patients having depression (Becker et al., 1997; 
Walter et al., 2007a,b; Berg et al., 1999). 
In only a small sample of our PD patients, antidepressants were used at the 
assessment time: in the PD group, 6.8% with mild and 13.7% with severe 
depressive symptoms, antidepressants were used. Patients who were using 
antidepressants had significantly higher BDI scores than those who were not. It 
has been shown that 50 to 60 percent of PD patients do not achieve an adequate 
therapeutic response following a course of antidepressants (Fava, 2003). 
Importantly, low echogenicity of the brainstem raphe is a common finding in 50 
to 70 percent of patients with depression (Becker et al., 1994; Walter et al., 
2007b) and is associated with significantly lower responsiveness to serotonin-
reuptake inhibitors (Walter et al., 2007a). 
The present study illustrated the significance of the finding that TCS of 
brainstem raphe echogenicity could be used as a non-invasive biomarker to 
improve detection of depressive symptoms in early PD stages where clinicians 
may not recognize affective disturbances in the context of PD phenomena. 
However, the sensitivity and specificity of brainstem raphe echogenicity as a 
predictor of depression in PD or controls is yet to be reported.  
The level of affective disorders was directly related to the anatomical 
changes of brainstem raphe. Decreased echogenicity of the mesencephalic raphe 
has been found in 40 to 60 percent of patients with PD patients having 
depression (Becker et al., 1997; Walter et al., 2007a,b; Berg et al., 1999). 
Higher severity of depressive symptoms has been associated with longer PD 
disease duration, more severe motor and cognitive impairment, and advanced 
stage of the disease. With an average prevalence of about 40%, ranging from 
27% to 76%, depression is one of the most common non-motor manifestations 
of PD (Ji Won Han et al., 2018; Kadastik-Eerme et al., 2016; Slaughter et al., 
2001; Reijnders et al., 2008). The onset of depression during late stages of PD 
has mainly been related to a broader monoaminergic deficit in combination with 
a higher occurrence of cognitive impairment (Braak et al., 2004). Depression 
may already occur before the onset of motor symptoms, suggesting that the 
neuropathological process of PD increases the risk of depression (Leentjens et 
al., 2003; Reijnders et al., 2008; Schuurman et al., 2002). 
Regarding specific weaknesses of the study and subsequent recom-
mendations for future studies, a psychiatric interview for diagnostic purposes in 
addition to various rating scales (both self- and clinician administered) of 
depression should be incorporated into the assessment procedure. A second 
brainstem raphe rater could be included in the study to strengthen the reliability 
of the imaging results. Taken together, our results must be seen as exploratory 
and must be interpreted with caution. 
Increased clinician awareness of PD depression and application of available 
diagnostic and treatment interventions could eliminate significant suffering in 
PD and enhance quality of life. The early awareness and treatment of old age 




logical, and pharmaceutical investigations. With this, it is vital to arrange the 




6.3. Asymmetry of clinical symptoms of PD,  
and the effect of age on SN+ 
The motor symptoms usually affect the body asymmetrically at first with the 
initially affected side remaining most prominently affected throughout the 
disease course (Djaldetti et al. 2006). The functional asymmetry in PD is also 
reflected in the SN pathology. The SN corresponding to the disease onset side 
(in the following onset SN+) experiences a more dramatic loss of dopaminergic 
neurons than the contralateral side (in the following termed non-onset SN+) 
(Kempster et al. 1989). It has been reported that PD patients with a more 
extended hyperechogenic signal had an earlier disease onset (Berg et al. 2001). 
Others, however, could not replicate this finding and argued that the enlarged 
SN hyperechogenicity on TCS is an important factor in determining the disease, 
but should be treated as one of many factors associated with the disease and 
disease onset.  
In order to establish whether SN+ values are laterally different, the onset and 
non-onset SN+ were studied separately in the PD group and it was established 
that the area of SN+ on the right and left side were not statistically different. 
Our findings show that the area of SN+ is different in size depending on the side 
of PD symptom onset. Onset SN+ corresponding to the SN+ contralateral to the 
side with initial motor signs was on average 17.6% larger than non-onset SN+. 
We found a correlation with a higher age in PD patients and a slight but 
significant decrease in SN echogenicity contralateral to the side of the initial 
motor symptoms. This is supported by a previous report that documented a 
negative correlation between age at disease onset and SN+ (Walter et al., 
2007a). The underlying cause between age at disease onset and SN+ area has 
not yet been convincingly demonstrated. However, a post mortem investigation 
has reported a PD duration-related decrease in the density of intranuclear 
Marinesco bodies in the SN (Abott et al. 2017). Another hypothesis for the 
‘neurodegeneration’ of the SN on the primarily affected side could be a disease 
duration-related cell loss and an accompanying decrease in echogenic molecules 
(e.g. iron). However, age may account for a number of stressors within SN, 
weakening and/or losing the neurons function and their ability to react to further 
damages associated with the disease process. Moreover, it could be speculated 
that an SN+ at the onset side of PD results from active neuroinflammatory 
processes, which gradually diminish with the progression of PD and the 
decrease of the number of dopaminergic cells.  
In a cross-sectional study, we did not focus on the association between 




the exact onset of PD (which in many cases is not even clear to the patients 
themselves) but age is a measurable, clear parameter.  
Surprisingly, in our multiple regression analysis, the age failed to reliably 
predict the size area of SN+ ipsilateral to the side of the initial motor symptoms, 
though 42.5% of PD patients exhibited bilateral symptoms (HYS = 2). There 
could be several reasons why the non-onset SN+ demonstrates different area 
dynamics from onset SN+. Firstly, the extent of pathology of the non-onset side 
could appear later and to a lesser degree than the initially affected SN. Another 
reason might be the unilateral nature of the mechanisms triggering PD or at 
least that appear to be unilateral. For example, changes in the blood–brain 
barrier could allow pathogenic agents or toxic environmental factors to invade 
vulnerable structures preferentially on the more exposed side and thus limit the 
degenerative process mostly to one side (Berardelli et al., 2013). Furthermore, 
as the hyperechogenic area of the non-onset side is smaller than in the onset 
side, the changes may be harder to detect. It needs to be stressed, however, that 
it is currently unclear why PD symptoms generally occur asymmetrically and 
why the contralateral side becomes involved later on. 
The present study also invites a comparison in the SN+ in healthy individuals 
and PD patients – while the area of the initially affected SN decreases in PD, in 
healthy individuals it increases. The correlation was not very strong, but still is 
statistically significant (p < 0.01). This may be affected by the fact that the 
statistically significant correlation exists, but we should treat the medical 
significance with caution due to the large cohort where more significant results 
could be achieved. Moreover, I found the line to have a downward slope (r =  –
0.199). Thus age appears to be a factor in predicting the SN+ and influencing 
the dynamics of PD in our study. This is corroborated by a study of the life-long 
changes in the SN in healthy individuals (Hagenah et al., 2010). 
Our findings also reveal the effect of age on the area of hyperechogenicity at 
the anatomical site of the SN in healthy and diseased individuals – whereas the 
area of the primarily affected SN decreases in PD, it increases in healthy adults. 
We acknowledge that in PD-patients the hyperechogenicity of the onset side 
usually shows a larger area than the non-onset SN. In our Estonian PD cohort of 
266 patients, this was not the case for 67 patients (25% of the cohort), who had 
a smaller SN area on the onset side, while for 9 patients the area was the same 
for both sides.  
We found that older PD patients had a smaller hyperechogenic area than 
younger PD patients while in healthy people SN+ is positively associated with 
age. We do not know whether the triggering factor is younger age of PD onset 
or something else. This needs to be evaluated in further studies. In sum, 
however, we conclude that onset-side revealed a stronger correlation than only 
considering SN size irrespective of age and we may recommend to use onset-
side as the best measurement for evaluating PD patients. 
Findings of SN+ in PD patients expanded the research to subgroups such as 
clinical PD subtypes or genetic PD. Bilateral SN+ were more common in 




(Walter et al., 2007). Another study which reported larger SN sizes in non-
tremor-dominant patients compared to tremor-dominant PD (Lauckaite et al., 
2014). Accumulating evidence from independent studies prompted further 
efforts to understand the causes, consistency and significance of SN+ in PD. 
The side of the larger hyperechogenic area correlates with the clinically more 
affected contralateral side, indicating that SN+ size may be associated with 
clinical features or nigral pathology. Reports with regard to association between 
SN+ and disease specific features have been conflicting (Yilmaz et al., 2018). 
Although SN degeneration usually occurs bilaterally in PD, loss of dopaminergic 
neurons is more pronounced contralaterally to the initially clinically more 
affected body side (Kempster et al., 1989). As an enlarged SN+ seems to appear 
prior to motor symptoms, a smaller non-onset SN+ could be a sign of a delayed 
disease spread to the contralateral SN.  
On the other hand, the first two studies on TCS in PD showed no correlation 
between the size of the SN and age (Berg et al., 2001), a finding that was 
supported in patients with RBD (Iranzo, 2007) which showed an increasing 
prevalence of SN+ with age in elderly individuals. With regard to the 
association between SN+ size and motor disability, measurements revealed no 
such correlations (Iranzo et al., 2010; Jesus-Ribeiro et al., 2016; Lobsien et al., 
2012; Spiegel et al., 2006), contrary to the positive findings of others (Behnke 
et al., 2007, Sanzaro et al., 2014; Weise et al., 2009). A correlation between the 
SN+ size and disease duration or dopamine transporte uptake in functional 
imaging has also not been found in most studies (Lobsien et al., 2012; Spiegel 
et al., 2006). Nevertheless, more studies with longitudinal design are needed to 
elucidate this contentious issue. 
These findings further underscore the importance of differentiating between 
the onset and non-onset SN+. Several authors have reported a lack of change of 
bilaterally averaged SN+ as a function of PD duration leading them to conclude 
that SN+ is just a trait marker for PD that does not reflect the disease 
progression nor the state (Mehnert et al., 2010; Walter et al., 2007a).  
It is currently unclear whether the age-related increase in SN+ may overlap 
with PD pathophysiology or reflect an increased nigrostriatal vulnerability to 
PD (Berg et al., 2002). However, it is known that the SN is susceptible to iron 
accumulation (Bilgic et al., 2012), LB accumulation (Buchman et al., 2012) and 
neuronal loss (Ma et al., 1999), even in elderly individuals without clinically 
defined PD. This is perhaps a reflection of the high oxidative stress burden 
created by dopamine metabolism and the susceptibility to calcium overload in 
dopaminergic neurons (Reeve et al., 2014). We found that SN+ decrease in PD 
patients depended on the clinically first affected side, but it did not occur on the 
non-onset side, whereas in healthy people SN+ increases with age. This is my 
hypothesis that SN+ is higher in PD patients with a younger age of onset. 
As a limitation, we are not able to eliminate some methodological problems. 
Although the person performing transcranial sonography had no knowledge of 
the exact state and progression of the disease, he was not completely blinded to 




was performed after transcranial sonography by another investigator. Secondly, 
>10% of the participants (and 25% of female PD patients) did not have a 
sufficient bone window and thus could not undergo this examination. 
 
 
6.4. Future prospects 
In daily clinical practice, widely varying SN+ areas in PD patients are visible 
that do not correlate with duration of the disease, but in PD with a long duration 
the SN+ occurs in a smaller area than in patients who were diagnosed with PD 
recently. The long-term study statistic is in progress, to show possible change in 
SN+ values during the course of PD. The same study group is included in 
repeated assessments 7 years later, and some of control group subjects became 
PD during this period. 
The second part of the longitudinal study is the follow-up to identify if and 
in how many subjects among our primary healthy controls developed PD over 
the period of 7 years. By the 7th study year, we had 122 study control subjects 
available. The results of our performed studies are a good platform to move on 







The present study was the first TCS study to validate SN+ as a biomarker for 
PD in a large Estonian cohort. Around 10% of PD patients in Estonia were 
involved in the study, which showed the following findings: 
 
1.  The Estonian population has the same percentage of SN+ as other white 
populations. The highest diagnostic accuracy was achieved by the use of 
multiple TCS assessments to define SN+ which was 0.23 cm2 in the Estonian 
sample. Single measurements yielded higher sensitivity for the diagnosis of 
PD, while mean replicate measurements provided slightly higher specificity. 
This finding argues for performing multiple measurements to gain diagnostic 
certainty whenever possibl 
2.  The prevalence of mild (38.7%) and severe (35.7%) depressive symptoms in 
the patient sample was found to be significantly higher than in controls 
where mild depressive symptoms (26.8%) and severe depressive symptoms 
were 28.6%. BR echogenicity in both patients and controls was directly 
related to their total BDI score, although we found a significantly greater 
reduction of BR echogenicity in patients with PD and depressive symptoms 
compared to depressed non-PD controls. Only a small sample of PD patients 
were using antidepressants at assessment time (n=20). Of those, 6.8% with 
mild and 13.7% with severe depressive symptoms were using anti-
depressants. In the controls nobody used antidepressants. 
In both patients and controls, severe depressive symptoms were related to 
reduced brainstem raphe echogenicity by TCS that allows to use brainstem 
raphe as a non-invasive ultrasound marker for diagnosing depressive 
symptoms in the early stages of PD when affective disorders may not be 
easily recognizable in the context of PD symptoms. 
3.  The size of SN+ is differentially affected depending on the side of disease 
onset. Onset SN+ corresponding to the contralateral side of the initial motor 
symptoms was on average 17% larger than the non-onset side measure. We 
found that elder PD-patients had a smaller hyperechogenic area than younger 
PD patients while healthy people SN+ is positively associated with age. The 
study did not detect similar interactions in the non-onset SN+. 
We conclude that onset SN+ is a better marker than the average 
measurement of both sides, hence onset SN+ should be taken into account 
while making the analysis, as this is much better describing the disease 
symptoms. We conclude that using onset-side gave us stronger correlation 
and we may recommend to use onset-side as the best measurement for 
evaluating PD patients. While we could say that larger measurement could 
be the second best option, as the correlation with the same negative trend 
exists taking into account the larger SN+. We may emphasize that evaluation 
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9. SUMMARY IN ESTONIAN 
Transkraniaalne aju ultraheliuuring Eesti parkinsoni tõve haigetel  
Parkinsoni tõbi (PT) on sageduselt teine liigutushäire. PT juhtivaks histopato-
loogiliseks muutuseks on Substantia nigra (SN) degeneratsioon ning tsüto-
plasmaatilised inklusioonid-Lewy kehakesed- degenereeruvates rakkudes. PT 
kliinilistele avaldustele eelneb pikaajaline prekliiniline periood (Obeso et al., 
2017). Kliiniliste sümptomite avaldumise hetkeks on dopamiini tase langenud 
20%ni normaalsest (Poewe et al., 2017). PT diagnoosimine võib olla keerukas, 
millele viitab asjaolu, et patoanatoomilisel uuringul ei kinnitunud diagnoos kuni 
25% haigetest (Hughes et al., 2002). Kuna haigus on hiiliva algusega ja selle 
esimesed sümptomid on sageli mittespetsiifilised, siis diagnoositakse PT 
tavaliselt mõne aasta jooksul pärast esmaste sümptomite tekkimist. Esmas-
sümptomiteks võivad olla ka nn mittemotoorsed sümptomid, mis võivad 
esineda ka ilma PT-ta: nt lõhnatundlikkuse alanemine, kõhukinnisus, unehäired 
ja depressioon (Walter et al. 2014b, Titova, et al., 2017). 
PT diagnoos on kliiniline; rutiinselt kasutatavaid radioloogilisi ega 
laboratoorseid diagnoosi meetodeid pole kasutusel nende hinna, samuti veel 
piisava tõenduspõhise teabe puudumise tõttu. Üheks innovaatilisemaks diag-
nostikameetodiks PT diagnostikas peetakse transkraniaalset aju ultraheli-
uuringut, mida esmaselt kirjeldas 1995. aastal Georg Becker, avastades keskajus 
leiduva substantia nigra hüperehhogeensuse (SN+) (Becker et al., 1995). 
Tänaseks on selgunud, et SN+ ei ole nähtav kõigil patsientidel. SN+ peetakse 
oluliseks bioloogiliseks markeriks varase PT esinemise hindamisel, kuivõrd 
seda on leitud üle 90% PT patsientidest (Berg et al., 2001). Sealjuures on 
ilmnenud, et SN+ on enamväljendunud kliinilisele sümptomaatikale vastas-
poolel (Berg et al., 2001). Kuigi SN+ esineb mõlemapoolselt, on see muutus 
asümmeetriline ja korreleerub hästi kliinilise leiuga, erinevalt nt Lewy 
kehakeste haigusest, mille puhul SN+ on enamasti sümmeetriline. Samuti on 
leitud, et SN+ oli enam väljendunud monogeense pärilikkuse tüübiga juhtudel. 
SN+ võib erinevate geneetiliste mutatsioonide korral varieeruda (Walter et al., 
2013). 
SN kajarikkaks ehk hüperehhogeenseks muutumise bioloogiline alus pole 
teada. Püstitatud on hüpoteesid, mis seostavad SN+ dopaminergiliste neuronite 
hävimisega, SN rakkude arvu vähenemisega, SN muutunud mahu või koe-
koostise muutumisega. Kõige enam on leitud muutusi SN rauasisalduses. Seni 
on loom- ja surmajärgsetes inimuuringutes õnnestunud näidata vaid SNs raua 
suurenenud sisaldust SN+ korral (Berg et al., 2006). Arvatakse, et SN suuremat 
ehhogeensust põhjustab ferritiiniga sidumata rauakoguse suurenemine. See 
arvamus toetub haigete surmajärgsetele uuringutele, kus SNis leiti neuro-
melaniini vähenenud kontsentratsioon ja raua kogunemist ning näidati 
positiivset korrelatsiooni H- ja L-ferritiini hulga ning SNi ehhogeensuse vahel 
(Berg et al., 2006). Lisaks raua kogunemisele on SN rakkude degeneratsioonis 




et al., 2004). PT haigete SNs esineb neuronaalsele degeneratsioonile järgnev 
gliiarakkude arvu suurenemine (Berg et al., 2010). Neuronite hukk ja gliia-
rakkude hulga kasv muudab neuronite ning gliiarakkude arvulist suhet ja võib 






1. Uurida prospektiivselt transkraniaalse aju ultraheliuuringuga SN esinemist 
PT põdeval ulatuslikul Eesti patsientide rühmal ja võrrelda saadud tulemusi 
tervetel samaealistel inimestel, leides parima diagnostilise täpsusega SN+ 
(cm2), mille abil edaspidi diagnoosida PT Eesti patsientidel. 
2. Kirjeldada PT põdevatel Eesti haigetel depressiivsete sümptomite ilmnemist 
ja nende seost ajutüves asuvate Raphe tuumade ehhogeensuse esinemise 
põhjal, lähtuvalt transkraniaalse aju ultraheli uuringust. 
3. Analüüsida ja kirjeldada, millistel tingimustel esineb SN+ asümmeetrilisus 
PT patsientidel ja milline on SN+ samaealistel tervetel uuritavatel. 
 
  
Uuritavad ja meetodid 
 
Uuringu kiitis heaks Tartu Ülikooli inimuuringute eetikakomitee. Kõik uuringus 
osalejad allkirjastasid teadliku nõusoleku vormi. Uuritavad leiti Ida-Tallinna 
Keskhaigla neuroloogiakeskuse ja Tartu Ülikooli Kliinikumi närvikliiniku 
neuroloogia osakonna andmebaasist. 
Uuring oli prospektiivne ja läbilõikeline, kus osales kokku 300 Parkinsoni 
tõve patsienti, kes vastasid Ühendkuningriigi Parkinsoni Tõve Ajupanga 
diagnoosikriteeriumitele, ja 200 samaealisest tervet kontrollisikut, kes leiti Ida-
Tallinna Keskhaigla Parkinsoni tõve patsientide lähedaste seast, vanemaealiste 
laulukoori liikmete ja nende abikaasade hulgast ning kaasabil, mõned uuritavad 
olid haigla personali seast ja mõned, kelle puhul polnud teada Parkinsoni tõbe, 
olid patsientidena ravil mõne muu mitte-neurodegeneratiivse haigusega (pea-
valu, neuropaatia). Parkinsoni haigetele oli eelnevalt läbi viidud neurovisuali-
seerimise uuring (kompuutertomograafia või magnetresonantstomograafia), 
kontrollgrupi liikmetele ei teostatud eelnevalt mingit aju visualiseerimis-
uuringut. 
Haigeid ja kontrollgrupi liikmeid intervjueeriti ning hinnati nende kliinilist 
neuroloogilist leidu: parkinsonistlikku staatust, haiguse raskusastet, kognitiivset 
funktsiooni, meeleolu. Küsitleti haiguse tekkeaja kohta. Kui patsient seda ei 
teadnud, kontrolliti esmassümptomite tekkeaega ja haigestumist patsiendi 
haigusloost. Kõiki kliinilisi teste viis läbi üks uurija, kes ei olnud teadlik hiljem 
teostatava transkraniaalse ultraheli uuringu tulemustest. 
Kliinilistest skaaladest kasutati järgmisi rahvusvaheliselt tunnustatud 




III), Hoehn Yahri skaalat (HYS), Schwab England (SE) igapäevaste tegevuste 
skaalat, mille abil hinnatakse inimese iseseisvust protsentuaalselt 0 –100 (100% 
on täiesti iseseisev, ei tunneta mingeid raskusi; 0% korral on säilinud vaid 
vegetatiivsed funktsioonid, vaimse seisundi miniuuringut (MMSE) ja Becki 
depressiooniküsimustikku, lõhnatundlikkuse hindamiseks kasutati Sniffin Sticks 
12-osalist lõhnapulkade testi. Patsientidel arvutati antiparkinsonistlike ravimite 
raviannused, kasutades levodopa ekvivalent-doosi arvutusskeemi. Trans-
kraniaalse aju ultraheli uuringu viis läbi teine uurija, kellel puudus infor-
matsioon kliiniliste testide andmete kohta. Kõik uuringu osad, nii kliiniline 
intervjuu, patsiendi läbivaatus kui transkraniaalne aju ultraheli uuring viidi läbi 
samal päeval. 
Transkraniaalne aju ultraheli uuring teostati pimendatud ruumis, patsient oli 
poollamavas asendis spetsiaalsel toolil. Ultraheli teostati ultraheliaparaadiga 
Logic 7, mil kasutati ultraheliandurit kiirgussagedusega 1.8–3.6 MHz (General 
Electric, USA). Kõikidel uuritavatel viis uuringu läbi üks uurija. Kõik uuringud 
viidi läbi ühesugust uurimismeetodit kasutades. Alustati kõrva ees asuva 
oimupiirkonna akustilise luuakna positsiooniga. Heaks uuringu teostamise 
orientiiriks oli orbitomentaaljoon, millega paralleelselt suunati ka ultraheli-
andur. Selle abil oli keskaju nähtav iseloomuliku hüpoehhogeense liblika-
kujulise struktuurina. Suurendusel oli keskajus lindikujulise struktuurina hästi 
nähtav SN, mida ümbritsesid hüperehhogeensed basaaltsisternid. Ajutüve sees 
keskjoonel asuvad hüperehhogeensed Raphe tuumad, mida kirjeldati kolme 
punkti skaalat kasutades; 2 – ei ole hinnatav; 1 – osaliselt hinnatav; 0 – täie-
likult hinnatav). 
Ultraheli andurit mõne kraadi võrra kraniaalsele kallutades ilmusid hüpo-
ehhogeensete struktuuridena kolmas ajuvatsake ja külgvatsakese eesmine sarv, 
olles ümbritsetud hüperehhogeense ependüümiga. Samuti asusid sellel tasandil 
taalamus ja basaalganglionid – sabatuum ja läätstuum, mis tervetel isikutel on 
madala ehhogeensuse tõttu praktiliselt eristamatud ümbritsevast valgeainest. 
Basaalganglione hinnati vastaspoolse oimuluu kaudu. SNi peetakse hüperehho-
geenseks, kui see peegeldab ultrahelisignaali ebanormaalselt suure intensiiv-
susega ümbritseva valgeainega võrreldes või kui ehhogeense struktuuri pindala 
on suurem kui tervete isikute kontrollvalimis. SN leidmisel seisati ultraheli-
aparaadi ekraanile kuvatud pilt, suurendati seda 2–3 korda ja ümbritseti seejärel 
kursorjoonega kõige laiemas kohas. Selle alusel leiti ultraheliaparaadi 
arvutusliku mõõtmise tulemusel ristlõikepindala (cm2). Samasugust uuringut 
teostati ühel patsiendil kolmel järjestikusel korral paremal ja vasakul poolel. Nii 
arvutati kõigi kuue mõõtmise keskmine, kolme mõõtmise keskmised paremal ja 
vasakul ning hinnati ühe mõõtmise tulemused. Enamiku seadmete puhul on 
normileiuks SN+ pindala alla 0,2 cm2 ning väärtused üle 0,25 cm2 liigitatakse 
selgelt hüperehhogeenseks. Kõigil uuritavatel hinnati kõiki kliinilisi para-
meetreid ja ultraheli mõõtmistulemusi samaaegselt ühe protokolli alusel. 






Uurimistöö tulemused ja arutelu 
 
Uuringust jäid välja isikud, kelle ultraheliuuringu tulemust ei olnud halva 
luuakna läbitavuse tõttu võimalik hinnata. Parkinsoni haigete grupist langes 
välja 34 isikut ja kontrollisikute grupist 32 isikut. Enam langes uuringus välja 
PT grupist naisi (25%); mehi (9%). Kontrollgrupist langes välja 12% naisi ja 
6% mehi. 
Kirjanduse andmetel võib sagedasemaks halva luulise läbitavuse põhjuseks 
olla osteoporoos või oimuluu paksus. Meie ei uurinud konkreetsete uuritavate 
väljalangemise põhjust. Seega jäi hinnatavate uuringugruppide suuruseks 266 
Parkinsoni tõve haiget vanuses 37 kuni 87 aastat ja 168 tervet kontrollisikut 
vanuses 50 kuni 86 aastat. 
Haiguse anamneesile toetudes leidsime, et uuringuhetkeks oli esmaste 
sümptomite tekkimisest möödunud 6,1±5,2 aastat, vahemikus 1–25 aastat. 
Keskmine MDS UPDRS III motoorne skoor oli haigetel 31,23±15,1 ja 
kontrollisikutel 3,0±2,2. Lõhnatesti 12 lõhnast tundsid haiged 5,6±0,19 ja terved 
8,6±0,18. Parkinsoni haigete levodopa ekvivalentdoos oli 418±366 mg. 
Transkraniaalsel sonograafial leitud SN+ mõõtmistulemuste alusel leidsime, et 
parim diagnostiline täpsus haigete ja tervete grupi liitmisel oli SN+ 0,23cm2, 
mis leiti kolme mõõtmistulemuse liitmisel paremalt ja vasakult. SN+ 0,23cm2 
andis parima sensitiivsuse 88,7% ja spetsiifilisuse 92,2% nn mitme mõõtmise 
keskmise arvutamisel. Pisut ebatäpsem oli SN+ (0,23cm2) mitme mõõtmise 
mediaani arvutamisel, kuid mitte statistiliselt olulise vahega. Üksikmõõtmise 
SN+ 0,21cm2 andis küll parema sensitiivsuse 93.2%, kuid halvema spetsiifi-
lisuse 85.1%, mistõttu mitme mõõtmise ja üksikmõõtmise võrdluses oli mitme 
mõõtmise tulemus statistiliselt erinev (p=0,0021). Kuivõrd mitme mõõtmise 
keskmise ja mediaani vahel oluline statistiline vahe (p=0,18) puudub, on 
igapäevases töös kolme mõõtmise keskmise kasutamine piisav. Kasutades 
optimaalselt parimat diagnostilist SN+ 0,23cm2, kasutasime sama näitajat 75 ja 
90 protsentiilidele vastavalt tervetel isikutel ja leidsime, et 75 protsentiili näitaja 
juures 0,18 ja 90 protsentiili näitaja 0,22cm2, suudab meie saadud tulemus 
0,23cm2 eristada haiged tervetest (AUC, 96,4; p<0.0001). Leidsime, et Eesti 
rahvastikul on võrreldes teiste riikide kirjeldatud üldrahvastikuga sarnane SN+ 
ning parimaks diagnostiliseks väärtuseks haigete ja tervete eristamisel Eesti 
rahvastikus on SNi pindala 0,23 cm2. 
Kasutades depressioonisümptomite raskust BDI skaala alusel ja Raphe 
tuumade ehhogeensuse hindamise skaalat, esines nende vahel oluline seos 
(p<0,001). Tervetel kontrollgrupi isikutel, kellel olid Raphe tuumad kas täie-
likult või osaliselt nähtavad, leidus ka vähem depressiooni sümptomeid. Samas, 
kui võrdlesime PT ja tervete gruppi eraldi, ilmnes Raphe tuumade nähtavuse 
korral statistiline erinevus vaid osaliselt. Kõrgem BDI skoor kinnitas raskemate 
depressiivsete sümptomite olemasolu, mis omakorda oli otseselt seotud suurema 
vanusega, pikema haiguskestvuse ja raskema toimetuleku häirega. Raphe 
tuumade ehhogeensus oli statistiliselt olulisemalt seotud BDI raskema skooriga 




korrelatsioon BDI skoori, Raphe tuumade ehhogeensuse, vanuse, haiguse 
kestvuse ja HYS’ga (r=0,5, p<0,001). BDI alusel esines kergeid depressiooni-
sümptomeid 38,7% ja raskeid 35,7% patsientidest ning kergeid depressiooni-
sümptomeid 26,8% ja raskeid sümptomeid 28,6% kontrollisikutest. Vaid väike 
arv uuritavatest kasutas uuringu hetkel antidepressante (n=20; 7,5%). Kerge 
depressiooni sümptomitega oli 6.8% ja raske depressiooni sümptomitega 13,7% 
patsientidest. Neil uuritavatel, kes kasutasid antidepressante, olid depressiooni 
sümptomid väljendunumad 
Kolmandas uuringus selgus, et SN+ on suurem Parkinsoni tõve haigete 
grupis (0,33 ± 0,10 cm2) kui tervete kontrollisikute grupis (0,16± 0,05 cm2, 
p<0.001). Statistilist erinevust ei ilmnenud aga vasaku ja parema SN+ vahel 
(vasakul 0.35± 0.11cm2; paremal: 0,36± 0.13cm2, p=0,31). Sealjuures esines 
oluline statistiline erinevus paaristesti alusel, (p<0,001) olles SN+ sõltuvalt 
esmaste haigusümptomitele vastaspoolses SNs. Nii oligi esmassümptomitega aju-
poolel SN+ (0.35±0,12cm2) ja mitte-esmassümptomite ajupoolel (0,30±0,10cm2), 
erinedes kahe poole võrdluses 17,6%. Multiipelset lineaarregressiooni mudelit 
kasutades leidsime, et kliinilised parameetrid nagu patsiendi vanus, HYS, MDS 
UPDRS III osutusid statistiliselt oluliseks SN+, olles seotud esmaste haigus-
sümptomite avaldumisega (p=0.0015). Taoline seos puudus mitte-esmas-
sümptomitega SN+ (p=0,17). Lisaks uurisime, kuidas väljendub SN+ eakatel 
haigetel ja tervetel ning leidsime, et SN+ on erineva olemusega. SN+ suureneb 
tervetel vanuse tõustes ja väheneb esmaste haigussümptomitega seoses. 
Võimalik, et see on seotud efektiga, et mida kauem on haigus kestnud, seda 
enam SN+ väheneb ja vastupidi, mida vanemaks inimene elab, seda enam SN+ 





Läbiviidud uuring oli esimene transkraniaalse aju ultraheliuuring Eestis, mis 
viidi läbi ulatuslikus PT patsientide ja tervete kontrollgrupi isikute valimis. PT 
patsientidest moodustas uuritavate hulk peaaegu 10%. Valideerisime parima 
diagnostilise väärtusena kasutatava SN+ eesmärgiga diagnoosida Eesti elanikel 
PT esinemist. 
1. Eesti valimi SN+ ei erine teiste riikide valge rassi vastavate valimitega 
võrreldes. Parim diagnostiline väärtus, mis eristas terveid haigetest ja diag-
noosis PT Eesti valimis, oli 0,23cm2, sensitiivsusega 88,7% ja spetsiifi-
lisusega 92,2%. Seejuures kasutasime mitme mõõtmise tulemuse aritmeetilist 
keskmist võrrelduna mediaanväärtuse või üksikmõõtmise meetoditega. 
2. Transkraniaalse aju ultraheliuuringul hinnatav Raphe tuumade terviklikkuse 
määramine on hea meetod, et välja selgitada varjatud depressiooni sümpto-
meid, kus patsient neid ei tunnista või hindab ennast valesti. Raphe tuumade 





3. SN+ asümmeetrilisus on seotud esmassümptomite tekkimisega ja meie 
uuringus on uuritavate vanus olulisim SN+ asümmeetria mõjutaja. SN+ 
suureneb tervetel vanuse tõustes. Esmaste haigussümptomitega seonduvalt 
SN+ väheneb. SN+ annab teavet haiguse kulu kohta ja võib olla parem bio-
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